{
"id":"mk19_a_gm_s9",
"subspecialtyId":"gm",
"title":"Mental and Behavioral Health",
"jsonContent":{
"type":"section",
"id":"mk19_a_gm_s9",
"title":{
"__html":"Mental and Behavioral Health"
},
"titleNode":{
"type":"section-title",
"hlId":"39f3e9",
"children":[
"Mental and Behavioral Health"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_gm_s9_1",
"title":{
"__html":"Mood Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"a7a4bb",
"children":[
"Mood Disorders"
]
},
"children":[
{
"type":"p",
"hlId":"c3d9f3",
"children":[
"Mood disorders are characterized by elevated or depressed mood associated with psychomotor, cognitive, and/or vegetative symptoms that cause significant functional impairment. The two main groups of mood disorders are depressive disorders and bipolar disorder."
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_1_1",
"title":{
"__html":"Depressive Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"980420",
"children":[
"Depressive Disorders"
]
},
"children":[
{
"type":"p",
"hlId":"15cf5b",
"children":[
"The lifetime prevalence of depressive disorders in developed countries is approximately 20%. Women are affected almost twice as often as are men. Peak onset is in the fifth decade of life, and incidence decreases in the elderly population. Depression is the leading cause of disability in the United States among individuals aged 15 to 44 years and is a major risk factor for suicide."
]
},
{
"type":"p",
"hlId":"295a7f",
"children":[
"Depressive disorders often initially present in the primary care setting but are underdiagnosed because screening is underperformed. Depressive symptoms are frequently encountered in patients with chronic medical disease, either as a direct result of the illness or as a response to illness-related disability. Depression commonly accompanies thyroid disease, cancer, neurologic diseases (Parkinson disease), heart failure, HIV infection, inflammatory bowel disease, and diabetes mellitus. Medications, including glucocorticoids and interferon, may also trigger depressive symptoms. During evaluation for depression, clinicians must assess for these secondary causes."
]
},
{
"type":"p",
"hlId":"58ed8e",
"children":[
"The U.S. Preventive Services Task Force (USPSTF) recommends screening all patients for depression; adequate systems should be in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up. For such general population screening, the two-question PHQ-2 is effective and easy to use. If a patient provides a positive response to either of the questions (“Over the past 2 weeks, have you felt down, depressed, or hopeless?” and “Over the past 2 weeks, have you felt little interest or pleasure in doing things?”), further investigation for depression, including inquiring about suicidal ideation, is warranted."
]
},
{
"type":"p",
"hlId":"2ecb8c",
"children":[
"Depressed patients must be specifically asked about suicidal ideation and behavior. Positive or equivocal answers should be followed by questions related to means and intent; assessment of risk factors for suicide ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gm_t45",
"wrapId":"1",
"children":[
"Table 45"
]
}
]
},
")"
]
},
"; and the development of a plan for evaluation and care, which may include referral to the emergency department or a psychiatrist."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_a_gm_t45"
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_1_1_1",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_gm_s9_1_1_1_1",
"title":{
"__html":"Major Depressive Disorder"
},
"titleNode":{
"type":"section-title",
"hlId":"77ae23",
"children":[
"Major Depressive Disorder"
]
},
"children":[
{
"type":"p",
"hlId":"7a5ee4",
"children":[
"The DSM-5 criteria for diagnosis of major depressive disorder (MDD) require the presence of at least five symptoms, at least one of which must be depressed mood or anhedonia, nearly every day or all of the time during the same 2-week period. Symptoms of MDD and other mood disorders are outlined in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gm_t46",
"wrapId":"2",
"children":[
"Table 46"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_a_gm_t46"
]
},
{
"type":"p",
"hlId":"eab7fa",
"children":[
"For a diagnosis of MDD, symptoms cannot be attributable to a medical condition, medication, or substance use and must cause significant functional impairment. Clinicians should screen patients with depression for any history of elevated mood, which suggests bipolar disorder. Prescribing antidepressant monotherapy to a patient with bipolar disorder may precipitate mania."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_1_1_1_2",
"title":{
"__html":"Persistent Depressive Disorder"
},
"titleNode":{
"type":"section-title",
"hlId":"64c973",
"children":[
"Persistent Depressive Disorder"
]
},
"children":[
{
"type":"p",
"hlId":"624692",
"children":[
"Previously known as dysthymia, persistent depressive disorder is characterized by depressed mood most of the time for at least 2 years with at least two associated symptoms (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gm_t46",
"wrapId":"3",
"children":[
"Table 46"
]
}
]
},
")"
]
},
". The burden of symptoms is less than in MDD but still cause impairment of social or occupational functioning. Symptoms can temporarily resolve but do not abate for more than 2 months at a time."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_a_gm_t46"
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_1_1_1_3",
"title":{
"__html":"Seasonal Affective Disorder"
},
"titleNode":{
"type":"section-title",
"hlId":"9c839b",
"children":[
"Seasonal Affective Disorder"
]
},
"children":[
{
"type":"p",
"hlId":"f155d6",
"children":[
"Seasonal affective disorder (SAD) is defined as MDD, mania, or hypomania with recurrent seasonal onset and resolution. SAD is not a separate diagnostic entity; rather, it is a subtype of each of these mood disorders (with the specifier “with seasonal pattern”). The most common form of SAD is MDD with symptoms arising during autumn or winter and subsiding the following spring for at least 2 consecutive years (MDD with seasonal pattern); seasonal episodes of depression should substantially outnumber nonseasonal episodes. The diagnostic criteria are otherwise the same as for MDD."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_1_1_1_4",
"title":{
"__html":"Premenstrual Dysphoric Disorder"
},
"titleNode":{
"type":"section-title",
"hlId":"0c505d",
"children":[
"Premenstrual Dysphoric Disorder"
]
},
"children":[
{
"type":"p",
"hlId":"99ab14",
"children":[
"Premenstrual dysphoric disorder consists of symptoms of mood disturbance that develop the week before menses, remit within a week after menses, and occur with most menstrual cycles during a given year (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gm_t46",
"wrapId":"4",
"children":[
"Table 46"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_a_gm_t46"
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_1_1_1_5",
"title":{
"__html":"Peripartum Depression"
},
"titleNode":{
"type":"section-title",
"hlId":"40efb1",
"children":[
"Peripartum Depression"
]
},
"children":[
{
"type":"p",
"hlId":"2e7556",
"children":[
"Peripartum depression affects 7% of pregnant or postpartum women and is characterized as MDD occurring during pregnancy or within 4 weeks after delivery. It is not considered a separate mood disorder; instead, it is a subtype of MDD with the specifier “with peripartum onset.” The USPSTF recommends counseling interventions, such as cognitive behavioral therapy (CBT) and interpersonal therapy, to prevent peripartum depression in at-risk patients. However, there are no accurate screening tools for identifying women at risk for perinatal depression. Instead, the USPSTF recommends the pragmatic approach of offering counseling interventions or referral to women with one or more of the following risk factors: history of depression, current depressive symptoms (that do not reach a diagnostic threshold), low income, adolescent or single parenthood, unplanned pregnancy, recent intimate partner violence, elevated anxiety symptoms, gestational or pregestational diabetes, pregnancy complications, or a history of significant negative life events."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_1_1_1_6",
"title":{
"__html":"Persistent Complex Bereavement Disorder"
},
"titleNode":{
"type":"section-title",
"hlId":"58c326",
"children":[
"Persistent Complex Bereavement Disorder"
]
},
"children":[
{
"type":"p",
"hlId":"8a47ff",
"children":[
"Grief is a normal response to interpersonal loss, such as death of a loved one. The grief process varies, but most patients functionally adapt to loss within 12 months. Pathologic grief persists longer and is associated with significant impairment of function. This response to grief is termed complicated grief or persistent complex bereavement disorder (as proposed in DSM-5 as a future diagnostic classification) (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gm_t46",
"wrapId":"5",
"children":[
"Table 46"
]
}
]
},
")"
]
},
". Up to 10% of bereaved patients develop persistent complex bereavement disorder, but the incidence is doubled in patients with other mood disorders. Other risk factors include older age, loss of a spouse or child, and sudden death of a loved one. A major life loss can also induce other mood disorders; therefore, clinicians should maintain a high index of suspicion for these disorders in the bereaved patient."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_a_gm_t46"
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_1_1_1_7",
"title":{
"__html":"Adjustment Disorder With Depressed Mood"
},
"titleNode":{
"type":"section-title",
"hlId":"615a49",
"children":[
"Adjustment Disorder With Depressed Mood"
]
},
"children":[
{
"type":"p",
"hlId":"6749d9",
"children":[
"Patients may exhibit depressive symptoms in response to a stress- or trauma-related life event. Adjustment disorder with depressed mood is present when symptoms can be clearly linked to an identifiable stressor but criteria for other depressive disorders are not met. Symptoms resolve within 6 months of resolution of the stressor."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_1_1_2",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"71b151",
"children":[
"Most patients with MDD can be successfully managed in the primary care setting. Referral to a psychiatrist is indicated for patients with severe depression, failure of initial therapy, complex psychiatric comorbidities, or high suicide risk (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gm_t45",
"wrapId":"6",
"children":[
"Table 45"
]
}
]
},
")"
]
},
". For initial acute therapy, either CBT or second-generation antidepressants (SGAs) are indicated, with the choice of treatment based on a discussion of side effects, cost, accessibility, and patient preferences. It is unclear whether combination therapy with CBT and medication is more effective than either treatment modality alone, but combination therapy is reasonable in moderate to severe disease. Other psychological therapies are available as second-line options ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gm_t47",
"wrapId":"6",
"children":[
"Table 47"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_a_gm_t45",
"mk19_a_gm_t47"
]
},
{
"type":"p",
"hlId":"810035",
"children":[
"Four classes of SGAs are available: selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), serotonin modulators, and atypical antidepressants ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gm_t48",
"wrapId":"7",
"children":[
"Table 48"
]
}
]
},
")"
]
},
". Drug selection should be based on side effect profiles and patient-specific characteristics. Side effects are common, and patient education regarding adverse effects can improve adherence. SSRIs are generally well tolerated but can cause reduced sexual desire, anorgasmia, and delayed orgasm. Bupropion causes fewer sexual side effects, but it is contraindicated in patients with seizure disorders or a history of anorexia nervosa or bulimia. SSRIs, SNRIs, bupropion, and monoamine oxidase inhibitors all have the potential to cause serotonin syndrome, particularly if used in combination with one another or with other specific medications (including metoclopramide, tramadol, and linezolid) (see ",
{
"type":"cross-reference",
"target":"mk19_b_pm_s13_2_3",
"children":[
"MKSAP 19 Pulmonary and Critical Care Medicine"
]
},
")."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_a_gm_t48"
]
},
{
"type":"p",
"hlId":"bf94f3",
"children":[
"Medication should be started at a low dosage and gradually titrated to achieve a clinical response while monitoring for adverse effects. Therapeutic response can be objectively measured by comparing scores on the PHQ-9 before and during treatment. A decrease in score of at least 50% indicates a response to treatment; a decrease to a score of less than 5 indicates remission. If initial monotherapy fails to achieve an adequate response within 6 to 12 weeks, the next therapeutic steps are guided by the initial choice of therapy and the presence of any response. If a partial response occurs, increasing the dosage of the chosen medication or adding psychotherapy (if not already used) may be appropriate. If no response is seen, switching to another SGA or adding a second agent with or without psychotherapy is indicated. A second-line approach is the addition of an antipsychotic drug. FDA-approved antidepressant-antipsychotic combinations include olanzapine with fluoxetine, and aripiprazole or quetiapine with any antidepressant. In cases of resistant depression, electroconvulsive therapy is also safe and effective, although transient memory loss is a common adverse effect."
]
},
{
"type":"p",
"hlId":"374bd5",
"children":[
"Esketamine is a glutamate receptor modulator delivered via nasal inhalation that has recently shown promise as an adjunctive therapy for MDD with suicidal ideation and treatment-resistant depression. Unlike most pharmacologic treatments for depression, its antidepressant effect is immediate. Given the lack of data on long-term safety and efficacy and the complexity of managing severe treatment-resistant depression, referral to a psychiatrist to determine treatment appropriateness is reasonable."
]
},
{
"type":"p",
"hlId":"2d0981",
"children":[
"Approximately half of patients who respond to appropriate initial therapy (CBT or SGA monotherapy) develop recurrent depression after 1 year without continued treatment. The American Psychiatric Association recommends continuation therapy (treatment after resolution of a major depressive episode) for 4 to 9 months in patients who responded to acute therapy. The antidepressant dosage that was effective in acute treatment should be maintained in the continuation phase, and if psychotherapy was used, it should be continued. Patients with three or more previous major depressive episodes, persistent depressive disorder, or residual depressive symptoms should receive long-term maintenance therapy at a similar dosage. When long-term drug therapy is not indicated or must be stopped for other reasons, antidepressant medications should be gradually tapered to avoid discontinuation syndrome. The most common symptoms associated with discontinuation syndrome are dizziness, fatigue, headache, and nausea, typically occurring within 1 to 7 days of rapidly discontinuing antidepressants."
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_1_1_2_1",
"title":{
"__html":"Special Populations"
},
"titleNode":{
"type":"section-title",
"hlId":"e4c2a4",
"children":[
"Special Populations"
]
},
"children":[
{
"type":"p",
"hlId":"bf9872",
"children":[
"Persistent complex bereavement disorder may respond to both psychotherapy and pharmacologic therapy, which should be targeted to specific symptoms. SSRIs and SNRIs have demonstrated benefit in patients with depressive symptoms."
]
},
{
"type":"p",
"hlId":"6ff01e",
"children":[
"Premenstrual dysphoric disorder and peripartum depression are treated similarly to other forms of depression, but with additional attention to drug safety during pregnancy. SSRIs and SNRIs are associated with a low risk for teratogenicity, except for paroxetine, which may be linked to congenital cardiac malformations. All antidepressant medications are safe with breastfeeding."
]
},
{
"type":"p",
"hlId":"e77c1f",
"children":[
"MDD with seasonal pattern can be effectively treated with CBT and SGAs. Daily exposure to 10,000 lux of visible light for 30 to 60 minutes is also beneficial."
]
},
{
"type":"p",
"hlId":"54eee1",
"children":[
"Patients with concomitant pain syndromes may derive additional analgesic benefit from the use of SNRIs."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_1_2",
"title":{
"__html":"Bipolar Disorder"
},
"titleNode":{
"type":"section-title",
"hlId":"cd4b33",
"children":[
"Bipolar Disorder"
]
},
"children":[
{
"type":"p",
"hlId":"1264c1",
"children":[
"Bipolar disorder is characterized by major depressive episodes and periods of mania or hypomania. The prevalence is 1% to 3%, and women are affected slightly more often than are men. Onset typically occurs in early adulthood, and more than half of patients initially present with a major depressive episode. Bipolar disorder is the most expensive mental health problem and carries a high lifetime suicide risk."
]
},
{
"type":"p",
"hlId":"fcbe48",
"children":[
"Bipolar disorder is divided into two main categories: bipolar 1 and bipolar 2. Diagnosis of bipolar 1 disorder requires at least one episode of mania that is not explained by a medication effect, substance use, or a medical condition. The DSM-5 defines mania as an episode of at least 7 consecutive days of irritable, expansive, or elevated mood that interferes with social or occupational functioning and has at least three associated symptoms (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gm_t46",
"wrapId":"8",
"children":[
"Table 46"
]
}
]
},
")"
]
},
". Most patients with bipolar 1 disorder also experience major depressive episodes, and many experience periods of hypomania. Hypomania is defined by the same criteria as mania, except the duration is at least 4 consecutive days and symptoms do not cause severe functional impairment."
]
},
{
"type":"inline-wrap",
"wrapId":"8",
"contentIds":[
"mk19_a_gm_t46"
]
},
{
"type":"p",
"hlId":"9e2f02",
"children":[
"Patients with bipolar 2 disorder have periods of both hypomania and major depression but never mania. Cyclothymic disorder is characterized by multiple episodes of hypomanic and depressive symptoms that do not meet criteria for hypomania or major depression."
]
},
{
"type":"p",
"hlId":"4caa3b",
"children":[
"Identification of bipolar disorder by primary care physicians is critical because treatment of bipolar disorder with antidepressant therapy alone can precipitate mania. In evaluating patients with depressive symptoms, clinicians should inquire about previous episodes consistent with mania or hypomania, age at onset of any mood symptoms, and family history of mood disorders."
]
},
{
"type":"p",
"hlId":"7abcda",
"children":[
"Treatment of bipolar disorder should be directed by a psychiatrist. First-line medications include lithium, valproic acid, carbamazepine, and lamotrigine; psychotherapy plays an adjunctive role. Patients with acute mania typically require one of the aforementioned medications plus an atypical antipsychotic agent (aripiprazole, olanzapine, quetiapine). Severe bipolar depression may require a combination of first-line medications or adjunctive antipsychotics (fluoxetine plus olanzapine). Quetiapine is also effective as monotherapy for bipolar depression."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"52255a",
"children":[
"The U.S. Preventive Services Task Force advises screening all patients for depression at primary care visits."
]
},
{
"type":"keypoint",
"hlId":"bff240",
"hvc":true,
"children":[
"For initial acute treatment of major depressive disorder, options include cognitive behavioral therapy or second-generation antidepressants after consideration and discussion of side effects, cost, accessibility, and patient preferences; combination therapy is a reasonable option, especially in moderate to severe disease."
]
},
{
"type":"keypoint",
"hlId":"629dd5",
"children":[
"Peripartum depression may occur during pregnancy or within 4 weeks after delivery; treatment is similar to that for other forms of depression but with close attention to drug safety in pregnancy."
]
},
{
"type":"keypoint",
"hlId":"f71fd8",
"children":[
"Referral to a psychiatrist is indicated for patients with severe depression, failure of initial therapy, complex psychiatric comorbidities, or high suicide risk."
]
},
{
"type":"keypoint",
"hlId":"220d32",
"children":[
"Clinicians must assess patients with depression for any history of elevated mood, which would suggest bipolar disorder; prescribing antidepressant monotherapy to a patient with bipolar disorder may precipitate a manic episode."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_2",
"title":{
"__html":"Anxiety Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"032e33",
"children":[
"Anxiety Disorders"
]
},
"children":[
{
"type":"p",
"hlId":"1335c9",
"children":[
"Anxiety disorders are common, especially in women. The Women's Preventive Services Initiative suggests screening for anxiety in all women, including those who are pregnant or in the postpartum period. The USPSTF does not provide a recommendation regarding screening for anxiety, and there are no recommendations regarding screening for anxiety in men. Screening for anxiety may be combined with depression screening by using tools such as the PHQ-4 and the Hospital Anxiety and Depression Scale."
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_2_1",
"title":{
"__html":"Generalized Anxiety Disorder"
},
"titleNode":{
"type":"section-title",
"hlId":"9e8536",
"children":[
"Generalized Anxiety Disorder"
]
},
"children":[
{
"type":"p",
"hlId":"b3bb58",
"children":[
"Generalized anxiety disorder (GAD) is characterized by excessive anxiety about activities or events (occupation, school) that a patient finds difficult to control and occurs more days than not for at least 6 months. The anxiety causes significant distress and functional impairment. Diagnosis also requires the presence of three of the following physical symptoms (DSM-5): restlessness, being easily fatigued, irritability, muscle tension, sleep disturbance, and difficulty concentrating. The lifetime prevalence of GAD is 5% to 10%, and women are affected more often than are men. As many as 50% of individuals with mood disorders experience a comorbid anxiety disorder during their lifetime."
]
},
{
"type":"p",
"hlId":"1a08d4",
"children":[
"Patients with significant anxiety or multiple unexplained physical symptoms should be screened for GAD using the GAD-7 screening tool (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.adaa.org/sites/default/files/GAD-7_Anxiety-updated_0.pdf",
"target":"_blank"
},
"children":[
"www.adaa.org/sites/default/files/GAD-7_Anxiety-updated_0.pdf"
]
},
"). The shorter-form GAD-2 can be administered in less time and may be equivalent to the GAD-7 in screening for GAD in primary care populations. The initial evaluation of suspected GAD focuses on excluding anxiety as a physiologic effect of another medical condition (e.g., hyperthyroidism; substance use disorder; medication effect; and symptom-driven anxiety, such as anxiety secondary to dyspnea)."
]
},
{
"type":"p",
"hlId":"801df0",
"children":[
"CBT and pharmacotherapy are equally effective in the treatment of moderate-severity GAD, but patients with comorbid mood disorders are best treated with a medication that targets their concomitant illnesses. SSRIs, SNRIs, buspirone, and tricyclic antidepressants are all effective in the treatment of GAD ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gm_t49",
"wrapId":"9",
"children":[
"Table 49"
]
}
]
},
")"
]
},
". SSRIs and SNRIs are preferred first-line drugs because they have fewer side effects than tricyclic antidepressants and effectively treat comorbid behavioral disorders (unlike buspirone, which is thought to be effective for anxiety alone). For patients with severe GAD leading to profound functional impairment or with severe comorbid mood disorders, a combined approach of pharmacotherapy with referral for psychotherapy is preferred, and further evaluation by a psychiatrist is recommended. Although often prescribed, benzodiazepines are limited in their effectiveness to short-term control of severe symptoms during the initial treatment phase. Side effects and risk for addiction preclude longer-term use (>2-4 weeks). The GAD-7 can be useful for monitoring response to treatment."
]
},
{
"type":"inline-wrap",
"wrapId":"9",
"contentIds":[
"mk19_a_gm_t49"
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_2_2",
"title":{
"__html":"Panic Disorder"
},
"titleNode":{
"type":"section-title",
"hlId":"3989dc",
"children":[
"Panic Disorder"
]
},
"children":[
{
"type":"p",
"hlId":"0821b3",
"children":[
"Panic attacks are characterized by sudden onset and rapid escalation (within minutes) of extreme fear or anxiety along with at least four of the following: fear of dying, fear of losing control, palpitations, diaphoresis, tremor, dyspnea, sensation of choking, chest pain, nausea, dizziness, chills or heat sensations, paresthesia, and derealization (perception that the world is not real). Panic attacks are commonly encountered in the primary care setting both as a primary symptom of psychiatric illness and as a symptom associated with other medical conditions (asthma, arrhythmias, hyperthyroidism). Exclusion of secondary causes is a crucial step in the evaluation of panic attacks. Patients who experience panic attacks may also have comorbid depression and other anxiety disorders (GAD, posttraumatic stress disorder [PTSD])."
]
},
{
"type":"p",
"hlId":"fd10a2",
"children":[
"Panic attacks are a key feature of panic disorder but are not pathognomonic; up to one third of all adults will experience a panic attack during their lifetime in the absence of underlying panic disorder. DSM-5 diagnostic criteria for panic disorder include both persistent (>1 month) panic attacks and persistent worry about the recurrence of panic attacks or maladaptive behavior changes secondary to the attacks (e.g., avoidance of previous triggers)."
]
},
{
"type":"p",
"hlId":"72bad5",
"children":[
"Treatment of panic disorder involves CBT, pharmacotherapy, or both. SSRIs and SNRIs are first-line medications because of their favorable side effect profile and efficacy. Short courses of benzodiazepines can be used for acute symptom control, but long-term use is discouraged."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_2_3",
"title":{
"__html":"Social Anxiety Disorder"
},
"titleNode":{
"type":"section-title",
"hlId":"e7aa64",
"children":[
"Social Anxiety Disorder"
]
},
"children":[
{
"type":"p",
"hlId":"0cc812",
"children":[
"Previously known as social phobia, social anxiety disorder is associated with excessive anxiety or fear of criticism or humiliation in social or performance situations. Patients with social anxiety disorder may experience palpitations, flushing, dyspnea, chest pain, or even panic attacks in these situations. To meet DSM-5 diagnostic criteria, symptoms must be present for at least 6 months and cause significant functional impairment. Patients usually understand that their anxiety is excessive but continue to avoid social situations that trigger anxiety. Both CBT and pharmacotherapy with SSRIs and SNRIs are effective for treatment of social anxiety disorder, although overall evidence is of low quality. For patients with social anxiety disorder restricted to performance situations, CBT is preferred."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_2_4",
"title":{
"__html":"Specific Phobias"
},
"titleNode":{
"type":"section-title",
"hlId":"dfb28a",
"children":[
"Specific Phobias"
]
},
"children":[
{
"type":"p",
"hlId":"7b520b",
"children":[
"Specific phobias are among the most common types of psychiatric disorders. A specific phobia is diagnosed when a patient has unreasonable fear or anxiety for 6 months or longer, leading to avoidance of a specific situation or object and causing distress or impairment. Common phobias include the fear of heights, enclosed spaces, air travel, animals, and the sight of blood or injections. CBT is the mainstay of treatment. Exposure therapy, a specific kind of CBT, is preferred and consists of repeatedly exposing the patient to the source of the phobia in a controlled, and often graded, environment. Pharmacotherapy is generally not recommended for treatment of specific phobias, because little evidence exists to support its use. However, in certain situations, such as air travel phobia, benzodiazepines may be helpful."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"8488b5",
"hvc":true,
"children":[
"Cognitive behavioral therapy and pharmacotherapy are equally effective in the treatment of generalized anxiety disorder, but patients with comorbid mood disorders are best treated with a medication that targets their concomitant illnesses."
]
},
{
"type":"keypoint",
"hlId":"1faa48",
"children":[
"Cognitive behavioral therapy and pharmacotherapy with selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors are effective for treatment of social anxiety disorder and panic disorder."
]
},
{
"type":"keypoint",
"hlId":"ca6774",
"children":[
"A specific phobia is diagnosed when there is unreasonable fear and avoidance of a situation or object that persists for 6 months or more and causes distress; exposure therapy is the mainstay of treatment."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_3",
"title":{
"__html":"Posttraumatic Stress Disorder"
},
"titleNode":{
"type":"section-title",
"hlId":"a33967",
"children":[
"Posttraumatic Stress Disorder"
]
},
"children":[
{
"type":"p",
"hlId":"1f17b1",
"children":[
"PTSD is an increasingly recognized disorder triggered by at least one of the following: direct experience of or witnessing a traumatic situation, learning that a loved one experienced a violent or accidental event, or repeated or excessive exposure to details of a traumatic event (e.g., a social worker repeatedly exposed to cases of child abuse). Prevalence varies by population, gender identity, socioeconomic class, and profession, with increased rates of PTSD seen in first responders, members of the military, and marginalized populations. PTSD often occurs concomitantly with mood disorders and other anxiety disorders and is associated with increased risk for substance use and other medical conditions, including cardiovascular or autoimmune disease."
]
},
{
"type":"p",
"hlId":"c5e0cb",
"children":[
"Diagnosis of PTSD can be challenging because of the patient's desire to avoid discussing the event and the frequency of concomitant psychiatric disorders. The DSM-5 diagnostic criteria for PTSD are complex. In general, PTSD is characterized by intrusive memories of the traumatic event (recurrent nightmares or flashbacks), persistent avoidance of reminders or triggers (people or places), persistent negative changes in thoughts and mood (negative beliefs, anhedonia), and alterations in arousal and reactivity (irritability, exaggerated startle, sleep disturbance). Symptoms typically begin within 4 weeks of the traumatic event and need to be present for more than 1 month."
]
},
{
"type":"p",
"hlId":"cd2f9b",
"children":[
"CBT remains the cornerstone of treatment for PTSD. Therapy focuses on generalized behavioral processing and treatment of associated symptoms. Mindfulness therapies are also emerging as an effective treatment for reducing PTSD symptoms. Antidepressants, including SSRIs (paroxetine, sertraline), SNRIs (venlafaxine), and nefazodone, are effective adjunctive therapies. Interest in treating PTSD with cannabinoid therapy is growing, and PTSD is a common indication in many state medical cannabis programs. However, there is a paucity of quality research to support cannabis as an effective intervention, particularly in light of the heterogeneity of available cannabis products."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"0c4958",
"hvc":true,
"children":[
"Cognitive behavioral therapy is first-line treatment for posttraumatic stress disorder."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_4",
"title":{
"__html":"Obsessive-Compulsive Disorder"
},
"titleNode":{
"type":"section-title",
"hlId":"64a2eb",
"children":[
"Obsessive-Compulsive Disorder"
]
},
"children":[
{
"type":"p",
"hlId":"8cb7b1",
"children":[
"Obsessive-compulsive disorder (OCD) has a lifetime prevalence of approximately 2%. Patients with OCD experience obsessions (recurrent and intrusive thoughts, images, or impulses causing distress) and compulsions (repetitive behaviors [hand washing, counting] done to alleviate obsession-related anxiety). These behaviors cause significant functional impairment through wasted time and disrupted social interactions. OCD is often accompanied by other mental health disorders."
]
},
{
"type":"p",
"hlId":"34d77b",
"children":[
"CBT is first-line treatment for OCD. CBT is more effective than pharmacotherapy alone, but SSRIs may be beneficial as adjunct therapy in patients with severe symptoms or inadequate response to CBT. The tricyclic antidepressant clomipramine is an alternative, although side effects are common. For patients treated with medication, the American Psychiatric Association recommends continued treatment for at least 1 to 2 years."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_5",
"title":{
"__html":"Substance Use Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"1b677b",
"children":[
"Substance Use Disorders"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_gm_s9_5_1",
"title":{
"__html":"Tobacco"
},
"titleNode":{
"type":"section-title",
"hlId":"cfb993",
"children":[
"Tobacco"
]
},
"children":[
{
"type":"p",
"hlId":"d6f42a",
"children":[
"Despite a significant shift in public health behaviors and attitudes over the past 30 years, tobacco use remains the most common cause of preventable death in the United States, with all-cause mortality three to five times higher in smokers than in nonsmokers. Tobacco use increases the risk for multiple types of cancer, pulmonary diseases, diabetes, osteoporosis, and cardiovascular conditions. The benefits of quitting tobacco use begin immediately, and over decades, risks for many of the associated conditions decrease substantially."
]
},
{
"type":"p",
"hlId":"3b9d8a",
"children":[
"The USPSTF recommends that clinicians ask all adults about tobacco use, advise them to stop using tobacco, and provide behavioral interventions and approved pharmacotherapy to adult tobacco users ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gm_t50",
"wrapId":"10",
"children":[
"Table 50"
]
}
]
},
")"
]
},
". Abrupt cessation of tobacco use may result in higher long-term abstinence rates than gradually decreasing use, and combining behavioral counseling with pharmacotherapy is more effective than either modality alone. Effective counseling and behavioral resources include problem-solving guidance (e.g., developing a quit plan and overcoming barriers), motivational interviewing, social support, and telephone quit lines. There is a dose-response relationship between the intensity and frequency of counseling and quit rates, which seem to plateau after 90 minutes of total counseling."
]
},
{
"type":"inline-wrap",
"wrapId":"10",
"contentIds":[
"mk19_a_gm_t50"
]
},
{
"type":"p",
"hlId":"ec83f8",
"children":[
"All smokers without contraindications should additionally receive at least one of seven FDA-approved treatments for smoking cessation ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gm_t51",
"wrapId":"11",
"children":[
"Table 51"
]
}
]
},
")"
]
},
". Varenicline is superior to other treatments; combining varenicline with nicotine replacement is the most effective strategy. Moderate- and high-dose preparations of nicotine replacement therapy are more effective than lower-dose ones, and combining more than one type of nicotine replacement therapy (short-acting and long-acting) is more effective than monotherapy. Initiation of therapy, especially varenicline, before smoking is stopped may also increase quitting success rates. For stable patients with cardiovascular disease and hospitalized patients with acute coronary syndrome, the American College of Cardiology recommends either varenicline or combined short- and long-acting nicotine replacement therapy as first-line therapies."
]
},
{
"type":"inline-wrap",
"wrapId":"11",
"contentIds":[
"mk19_a_gm_t51"
]
},
{
"type":"p",
"hlId":"de32c3",
"children":[
"Although tobacco use has decreased overall, increasing use of electronic nicotine delivery systems (also known as e-cigarettes and vaping), particularly among young people, is creating new health concerns. Although e-cigarettes may have a benefit of harm reduction for established smokers, the nicotine-containing aerosol also includes other chemicals (e.g., formaldehyde, propylene glycol, and heavy metals) that may be harmful. E-cigarette associated lung injury may occur and result in severe acute pulmonary disease and death; it is highly associated with vaping products that contain tetrahydrocannabinol and vitamin E acetate. Use of e-cigarettes may also act as a “gateway” for young people, leading to smoking more traditional tobacco products. The National Academy of Sciences concluded that e-cigarettes are not without biological effects, including dependence, although not to the extent of combustible tobacco cigarettes. The implications for long-term effects on morbidity and mortality remain unclear. E-cigarettes should not be recommended for smoking cessation."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_5_2",
"title":{
"__html":"Alcohol"
},
"titleNode":{
"type":"section-title",
"hlId":"374441",
"children":[
"Alcohol"
]
},
"children":[
{
"type":"p",
"hlId":"f5e1ae",
"children":[
"Heavy alcohol use is the third leading cause of preventable death in the United States, and alcohol-related costs, the majority of which are related to binge drinking, are estimated to exceed more than $250 billion annually. Individuals with disordered alcohol use often interact with the health care system but rarely receive appropriate treatment; less than 10% of patients who may benefit from treatment for alcohol use disorder receive it."
]
},
{
"type":"p",
"hlId":"1dfcf5",
"children":[
"The USPSTF recommends routine screening for unhealthy alcohol use. Recommended screening tools include the Alcohol Use Disorders Identification Test (AUDIT) (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://pubs.niaaa.nih.gov/publications/Audit.pdf",
"target":"_blank"
},
"children":[
"https://pubs.niaaa.nih.gov/publications/Audit.pdf"
]
},
"), the abbreviated AUDIT-Consumption (AUDIT-C) (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.hepatitis.va.gov/alcohol/treatment/audit-c.asp",
"target":"_blank"
},
"children":[
"https://www.hepatitis.va.gov/alcohol/treatment/audit-c.asp"
]
},
"), and the single-question screen “How many times in the past year have you had five (four for women and adults age >65 years) or more drinks in 1 day?”. Patients with a positive screening result should be assessed for the presence of alcohol use disorder. Severity of the disorder and related health consequences, including hepatic, cardiac, and neurologic sequelae, should also be assessed. Comorbid psychiatric, chronic pain, and substance use disorders are often present and require interdisciplinary treatment and subspecialty referral."
]
},
{
"type":"p",
"hlId":"1f0eda",
"children":[
"Treatment should be tailored to the patient's risk level ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gm_t52",
"wrapId":"12",
"children":[
"Table 52"
]
}
]
},
")"
]
},
" and includes psychotherapy (CBT) and pharmacotherapy ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gm_t53",
"wrapId":"12",
"children":[
"Table 53"
]
}
]
},
")"
]
},
". Patients with liver disease, especially those with alcohol-related liver disease, should be counseled against the use of alcohol. Naltrexone and acamprosate are both recommended as first-line pharmacologic therapy for moderate to severe alcohol use disorder. The choice between naltrexone and acamprosate should be directed by pharmacologic considerations, patient preference, and the presence of comorbidities. Patients with alcohol-related liver disease, at-risk patients who do not respond to brief interventions, and patients with alcohol use disorder who do not respond to office-based therapies should be referred to addiction specialists."
]
},
{
"type":"inline-wrap",
"wrapId":"12",
"contentIds":[
"mk19_a_gm_t52",
"mk19_a_gm_t53"
]
},
{
"type":"p",
"hlId":"9bc31c",
"children":[
"Alcohol withdrawal is a common complication of alcohol use disorder. Minor symptoms, such as tremulousness, diaphoresis, and palpitations, can occur 6 hours after the last drink. Alcoholic hallucinosis (hallucinations without clouding of the sensorium) is typically seen 12 to 24 hours after cessation, and withdrawal seizures may occur within 12 to 48 hours of cessation of alcohol use. These effects are treated expectantly, although a significant percentage of patients will progress to severe withdrawal (delirium tremens). Delirium tremens usually begins 48 to 96 hours after the last alcoholic drink and manifests as autonomic activation (e.g., hypertension, tachycardia) and altered mental status. It is often preceded by mild symptoms of withdrawal or withdrawal seizures."
]
},
{
"type":"p",
"hlId":"cfd84f",
"children":[
"Many patients with alcohol withdrawal require hospitalization, although some low-risk patients can be safely managed in the outpatient setting. The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) is a 10-item scale with high positive and negative likelihood ratios for predicting severe alcohol withdrawal syndrome. Benzodiazepines are the safest and most effective method to manage withdrawal ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gm_t54",
"wrapId":"13",
"children":[
"Table 54"
]
}
]
},
")"
]
},
". After initial dosing to control symptoms acutely, a symptom-triggered approach using standardized instruments, such as the Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar), should be used to measure the severity of withdrawal and guide treatment. Phenobarbital, propofol, and dexmedetomidine may be useful in refractory cases."
]
},
{
"type":"inline-wrap",
"wrapId":"13",
"contentIds":[
"mk19_a_gm_t54"
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_5_3",
"title":{
"__html":"Drugs"
},
"titleNode":{
"type":"section-title",
"hlId":"626c25",
"children":[
"Drugs"
]
},
"children":[
{
"type":"p",
"hlId":"e6716a",
"children":[
"Illicit drug use occurs in 9% of the U.S. population. The most commonly used drugs are cannabis, prescription drugs, cocaine, hallucinogens, inhalants, heroin, and fentanyl. Internists play a central role in prevention, diagnosis, and management of substance use disorders, including identifying and managing medical comorbidities and reducing harm. Effective communication and screening can also help identify patients at risk for drug interactions. The USPSTF recommends screening for the use of illegal or nonprescribed psychoactive drugs in all adults aged 18 years or older as long as the physician can provide access to further diagnostic and treatment services. The USPTF makes no recommendation regarding routine screening for illicit drug use in adolescents, as there is insufficient evidence regarding the risks and benefits of this practice. Several screening tools are available, including the four-question National Institute on Drug Abuse Quick Screen. Treatment primarily involves psychotherapeutic support. Internists also play a role in harm reduction, ensuring that at-risk patients (such as injection drug users) receive appropriate vaccinations and referrals to needle exchange services."
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_5_3_1",
"title":{
"__html":"Marijuana"
},
"titleNode":{
"type":"section-title",
"hlId":"bf5c56",
"children":[
"Marijuana"
]
},
"children":[
{
"type":"p",
"hlId":"be8d9e",
"children":[
"Marijuana remains the most commonly used illicit drug, a definition that is increasingly challenging in the current regulatory atmosphere, in which state laws allowing medical and recreational cannabis use are expanding rapidly while federal law continues to classify cannabis as a schedule I substance. Evidence shows that cannabis use is increasing and that a majority of U.S. adults accept recreational legalization of cannabis."
]
},
{
"type":"p",
"hlId":"59cc9c",
"children":[
"Cannabis use has been associated with long-term medical and psychological adverse effects, including reduced cognitive function, depression, and anxiety. Pulmonary complications, such as worsening of underlying asthma, may occur. Cannabis hyperemesis syndrome, a recognized complication of heavy cannabis use, is characterized by recurrent nausea and vomiting that is often relieved by prolonged hot showers."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_5_3_2",
"title":{
"__html":"Opioids"
},
"titleNode":{
"type":"section-title",
"hlId":"394a71",
"children":[
"Opioids"
]
},
"children":[
{
"type":"p",
"hlId":"da3a5a",
"children":[
"Prescription opioid use has emerged as a major cause of morbidity and mortality, necessitating coordinated medical and policy responses (see ",
{
"type":"cross-reference",
"target":"mk19_a_gm_s5_3_2_2_1",
"children":[
"Pain"
]
},
" for a discussion of opioid risk assessment and mitigation). Opioid use disorder is characterized by use of opioids in increasing amounts or for longer than intended, continued use of opioids despite impaired social functioning, repeated episodes of withdrawal, abandonment of important events or activities, and physical and psychological problems. Internists are increasingly treating opioid use disorder with pharmacotherapy in the office ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gm_t55",
"wrapId":"14",
"children":[
"Table 55"
]
}
]
},
")"
]
},
", and most patients with opioid use disorder will require extended pharmacotherapy. Psychosocial support and counseling may also be provided, although evidence of effectiveness is lacking."
]
},
{
"type":"inline-wrap",
"wrapId":"14",
"contentIds":[
"mk19_a_gm_t55"
]
},
{
"type":"p",
"hlId":"f18988",
"children":[
"A major complication of opioid use is overdose. The risk for opioid overdose is increased with higher doses and concurrent benzodiazepine prescription. Although nonfatal prescription opioid overdose presents an opportunity for intervention, most patients continue to receive opioids, and those receiving the highest dosage had the highest risk for repeated overdose. Nonmedical use of prescription opioids is a strong risk factor for heroin use, although the transition to heroin occurs at a low rate and is influenced by drug cost and availability."
]
},
{
"type":"p",
"hlId":"bd4c84",
"children":[
"Intranasal naloxone is an important adjunct therapy in opioid use disorder, with evidence demonstrating a reduction in overdose death when used. Naloxone kits and overdose prevention education should be provided to patients at increased risk for overdose, such as those receiving daily doses of 50 morphine milligram equivalents per day or more or those concurrently taking a benzodiazepine. Certain comorbid conditions, including COPD, obstructive sleep apnea, other substance use disorders, and mental health disorders, also increase the risk for opioid-related death. Other patients at high risk for overdose are those illicitly using opioids or stimulants contaminated with opioids, those with a history of opioid misuse who have recently been released from incarceration, and individuals receiving treatment for opioid use disorder. Friends, family members, and caretakers may also receive prescriptions and training in naloxone use."
]
},
{
"type":"p",
"hlId":"6bf3e9",
"children":[
"Opioid withdrawal is a common syndrome that results from either abrupt cessation of long-term opioid use or the administration of an opioid antagonist (naloxone). Onset of symptoms varies from immediate to several days later, depending on whether an opioid antagonist was administered and the duration of action of the opioid. Symptoms are nonspecific and include nausea, vomiting, diarrhea, and restlessness. Treatment depends on the individual situation; options include supportive care (e.g., antiemetics, benzodiazepines) and long-acting opioid agonists (e.g., methadone, buprenorphine)."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_5_3_3",
"title":{
"__html":"Stimulants and Hallucinogens"
},
"titleNode":{
"type":"section-title",
"hlId":"f942bd",
"children":[
"Stimulants and Hallucinogens"
]
},
"children":[
{
"type":"p",
"hlId":"7da84b",
"children":[
"Methamphetamines, cocaine, and substituted cathinones (“bath salts”) are stimulants of abuse that cause various associated conditions encountered in acute care settings. Management of toxicity of drugs of abuse, including stimulants and hallucinogens, is discussed in ",
{
"type":"cross-reference",
"target":"mk19_b_pm_s13_4_4",
"children":[
"MKSAP 19 Pulmonary and Critical Care Medicine"
]
},
"."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"71d727",
"children":[
"Clinicians should ask all adults about tobacco use, advise them to stop using tobacco, and provide behavioral interventions and approved pharmacotherapy to adult tobacco users."
]
},
{
"type":"keypoint",
"hlId":"285505",
"children":[
"Patients diagnosed with alcohol use disorder often require both psychotherapeutic and pharmacologic approaches to ensure safety and minimize relapse; naltrexone and acamprosate are first-line pharmacologic therapies."
]
},
{
"type":"keypoint",
"hlId":"b1bd11",
"hvc":true,
"children":[
"Patients at risk for opioid overdose, including those prescribed high-dose opioids and those being treated for or in recovery from opioid use disorder, should be offered naloxone."
]
},
{
"type":"keypoint",
"hlId":"ed1cf2",
"children":[
"All patients with opioid use disorder require extended treatment consisting of both psychosocial support and medication."
]
}
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_6",
"title":{
"__html":"Personality Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"8845a0",
"children":[
"Personality Disorders"
]
},
"children":[
{
"type":"p",
"hlId":"85dd48",
"children":[
"Personality disorders involve consistent patterns of interpersonal behavior and perceptions that are inflexible, diverge significantly from the behavioral standards of the person's culture, and cause substantial functional impairment and emotional distress. Development of these disorders usually occurs in adolescence, and the prevalence in the United States is estimated at 10% to 15%. Comorbid psychiatric illness is common. Three clusters of personality disorders have been defined on the basis of symptoms ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gm_t56",
"wrapId":"15",
"children":[
"Table 56"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"15",
"contentIds":[
"mk19_a_gm_t56"
]
},
{
"type":"p",
"hlId":"ef8846",
"children":[
"Personality disorders add challenges to patient care and can serve as a substantial barrier to care. Physicians should have open, sensitive discussions of the personality disorder diagnosis with the patient and emphasize the purpose of care. Such discussion may also make the patient more receptive to referral to a mental health professional. Establishing a relationship based on trust and clear boundaries can help facilitate care. Pharmacotherapy is a subject of ongoing investigation; however, no medications specifically treat personality disorders. Medications may be used to improve specific symptoms (e.g., mood stabilizers for impulsivity). Dialectical behavioral therapy can help patients improve coping mechanisms and behaviors."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_7",
"title":{
"__html":"Somatic Symptom and Related Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"702a17",
"children":[
"Somatic Symptom and Related Disorders"
]
},
"children":[
{
"type":"p",
"hlId":"77ea55",
"children":[
"Previously known as somatoform disorders, somatic symptom and related disorders are characterized by medically unexplained symptoms that cause emotional distress and psychosocial impairment. Prevalence is as high as 4%, and primary care is a common setting for presentation. Patients with these disorders have very high health care utilization rates yet are often dissatisfied with their care. Before diagnosing any of these disorders, clinicians should thoroughly evaluate for and optimize treatment of medical disease and other psychiatric disorders (e.g., depression, GAD). Many unexplained medical problems are related to unidentified organic pathology, and patients with known medical disease may have a concurrent somatic symptom or related disorder."
]
},
{
"type":"p",
"hlId":"2ff80e",
"children":[
"Medically unexplained symptoms that do not rise to the level of a psychiatric disorder are discussed in ",
{
"type":"cross-reference",
"target":"mk19_a_gm_s4_8",
"children":[
"Common Symptoms"
]
},
"."
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_7_1",
"title":{
"__html":"Types"
},
"titleNode":{
"type":"section-title",
"hlId":"f2d346",
"children":[
"Types"
]
},
"children":[
{
"type":"p",
"hlId":"fe6750",
"children":[
"Somatic symptom disorder (previously called somatization disorder) is characterized by one or more somatic symptoms that have been present for at least 6 months. These symptoms cause significant distress or interference with life and are associated with excessive thoughts, behaviors, and feelings related to the symptoms. When the main symptom is pain, “somatic symptom disorder with predominant pain” is the diagnosis (previously referred to as pain disorder)."
]
},
{
"type":"p",
"hlId":"e6e9a0",
"children":[
"Illness anxiety disorder (formerly known as hypochondriasis) is characterized by excessive concern about health and preoccupation with health-related activities (e.g., measuring pulse). In contrast to somatic symptom disorder, no symptoms or only mild somatic symptoms are present in illness anxiety disorder."
]
},
{
"type":"p",
"hlId":"d45995",
"children":[
"Conversion disorder involves at least one symptom of neurologic dysfunction (abnormal sensation or motor function) that is unexplained by a medical condition and not consistent with examination findings. Conversion disorder does not represent fabrication of symptoms but rather unexplained symptoms that do not have a pathophysiologic basis. These symptoms, which are functionally limiting, occur during times of substantial physical, emotional, or psychological stress."
]
},
{
"type":"p",
"hlId":"10ac9a",
"children":[
"Somatic symptom and related disorders must be differentiated from factitious disorder and malingering. Factitious disorder (formerly called Munchausen syndrome) is an intentional fabrication of symptoms or injury to oneself or another without clear external benefit. Malingering occurs when a patient feigns medical problems for gain; thus, malingering is not a psychiatric diagnosis."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_7_2",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"fcc257",
"children":[
"When treating patients with somatic symptom and related disorders, clinicians should acknowledge the patient's symptoms and focus on improving coping mechanisms and establishing regularly scheduled visits. Diagnostic testing and referral to specialists should not be requested solely to provide reassurance. CBT is effective for patients with somatic symptom disorder who are willing to undergo psychotherapy; antidepressant drugs also have demonstrated benefit. Illness anxiety disorder may respond to CBT, whereas disease education is the primary treatment for conversion disorder."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"aa365d",
"hvc":true,
"children":[
"When treating patients with somatic symptom and related disorders, clinicians should acknowledge the patient's symptoms and focus on improving coping mechanisms and establishing regularly scheduled visits."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_8",
"title":{
"__html":"Eating Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"0fbd92",
"children":[
"Eating Disorders"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_gm_s9_8_1",
"title":{
"__html":"Types"
},
"titleNode":{
"type":"section-title",
"hlId":"f2d346",
"children":[
"Types"
]
},
"children":[
{
"type":"p",
"hlId":"43bf13",
"children":[
"Approximately 3% of the U.S. population has an eating disorder. Disorders most likely to be encountered by internists include anorexia nervosa, bulimia nervosa, and binge eating disorder."
]
},
{
"type":"p",
"hlId":"34fd9f",
"children":[
"Anorexia nervosa is characterized by fear of weight gain and a distorted body image, with restriction of caloric intake relative to metabolic requirements that leads to below-normal body weight. DSM-5 further divides the disorder into subtypes: restricting type (no episodes of food binges or purging) and binge eating/purging type. Women are affected three to four times more often than are men, and onset most often occurs in adolescence."
]
},
{
"type":"p",
"hlId":"507324",
"children":[
"In bulimia nervosa, patients engage in binge eating followed by compensatory behaviors to prevent weight gain at least once weekly for 3 months. Compensatory behaviors include self-induced vomiting, laxative abuse, fasting, and excessive exercise. Binge eating is defined as eating substantially more food than most people would consume within a period of time. Similar to anorexia nervosa, patients with bulimia nervosa have a distorted body image. The key difference between the binge eating/purging type of anorexia nervosa and bulimia nervosa is that patients with anorexia have significant weight loss. Prevalence is three times greater in women than in men, and the median age of onset is 18 years."
]
},
{
"type":"p",
"hlId":"f5d874",
"children":[
"Binge eating disorder is more common than anorexia and bulimia nervosa. It is characterized by binge eating and feelings of loss of control around food that occur an average of at least once weekly for 3 months. Binging episodes include at least three of the following characteristics: abnormally rapid consumption, eating until uncomfortably full, consuming large amounts of food when not hungry, eating alone owing to embarrassment, and feelings of guilt related to overconsumption. These characteristics distinguish binge eating disorder from overeating. The lack of compensatory behaviors to avoid weight gain differentiates binge eating disorder from bulimia nervosa. Concurrent psychiatric disease, including personality, mood, and substance use disorders, is common."
]
},
{
"type":"p",
"hlId":"c39ff5",
"children":[
"Clues to the presence of an eating disorder on physical examination include findings suggesting malnutrition (muscle wasting, xerosis, and lanugo) and/or self-induced vomiting (erosion of dental enamel, parotid gland enlargement, and scarring or calluses on the dorsum of the hand)."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_8_2",
"title":{
"__html":"Medical Complications"
},
"titleNode":{
"type":"section-title",
"hlId":"53fd57",
"children":[
"Medical Complications"
]
},
"children":[
{
"type":"p",
"hlId":"c73653",
"children":[
"Multiple medical problems due to malnutrition can develop in patients with anorexia nervosa. Patients often exhibit signs of a hypometabolic state, including bradycardia, hypotension, hypothermia, and decreased gastrointestinal motility. Electrolyte abnormalities (hypokalemia, hypomagnesemia, and hypophosphatemia) can cause dysrhythmia and contribute to increased mortality. Refeeding syndrome can worsen these electrolyte disturbances; prevention requires gradual, carefully monitored increase of nutritional intake. Osteopenia and osteoporosis are common and may not be fully reversible if anorexia occurred during peak bone development in adolescence. Amenorrhea, anemia, and peripheral edema also occur frequently and usually resolve with recovery from anorexia nervosa."
]
},
{
"type":"p",
"hlId":"b7a851",
"children":[
"Purging behaviors may also cause electrolyte abnormalities. Self-induced vomiting may lead to upper gastrointestinal problems (esophagitis, esophageal tears), and laxative abuse may cause colonic dysmotility."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_8_3",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"950fe4",
"children":[
"The primary goal of treatment is reestablishing normal weight and eating behaviors. Psychotherapy, family therapy, and monitored dietary intake are the mainstays of treatment of anorexia nervosa. In some circumstances, hospitalization is required to ensure adequate emotional support, appropriate intake, and monitoring for refeeding syndrome. Involvement of a clinical nutritionist should be considered. Antidepressant therapy has not proved effective in treating anorexia nervosa, although low-dose olanzapine may be considered as adjunctive therapy for patients not responding to psychotherapy and nutritional interventions. CBT is the most effective intervention for bulimia nervosa and binge eating disorder; antidepressant therapy may be beneficial. Lisdexamfetamine and topiramate have also shown promise as adjunctive therapies to CBT in patients with binge eating disorder, and lisdexamfetamine is FDA approved for this indication. Bupropion should be avoided in patients with bulimia nervosa or anorexia nervosa because of increased risk for seizures."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"c636e6",
"hvc":true,
"children":[
"Psychotherapy and monitored dietary intake are the primary treatments for anorexia nervosa; antidepressant therapy is not effective."
]
},
{
"type":"keypoint",
"hlId":"0aa057",
"children":[
"Cognitive behavioral therapy is the most effective intervention for bulimia nervosa and binge eating disorder; antidepressant therapy, lisdexamfetamine, and topiramate may also be beneficial."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_9",
"title":{
"__html":"Schizophrenia"
},
"titleNode":{
"type":"section-title",
"hlId":"79ce9b",
"children":[
"Schizophrenia"
]
},
"children":[
{
"type":"p",
"hlId":"cb017f",
"children":[
"Schizophrenia is a heterogeneous psychiatric disorder comprising both positive symptoms (hallucinations, disorganized thought, delusions) and negative symptoms (flattened affect, decreased activity). Worldwide prevalence is approximately 1%, with a slight male predominance. The pathogenesis of schizophrenia remains unclear."
]
},
{
"type":"p",
"hlId":"3abe0a",
"children":[
"DSM-5 diagnostic criteria for schizophrenia require the presence at least two of the following: delusions, hallucinations, disorganized speech, disorganized or catatonic behavior, and negative symptoms. Diagnosis also requires at least one area of functional impairment (occupation, social interactions, or self-care) and duration of at least 6 months, including 1 month of active symptoms."
]
},
{
"type":"p",
"hlId":"2172b4",
"children":[
"Schizophrenia is associated with an increased risk for diabetes, cardiovascular disease, and obesity; these coexisting conditions may be exacerbated by the metabolic complications of antipsychotic therapy. Undertreatment of medical disease is common in this population. Mortality is significantly increased in patients with schizophrenia owing to coexisting conditions, behavioral disorders, and substance use. Approximately 5% of patients with schizophrenia die by suicide."
]
},
{
"type":"p",
"hlId":"310f53",
"children":[
"Schizophrenia is usually co-managed with a psychiatrist. Antipsychotic medications are highly effective at controlling positive symptoms of schizophrenia, but some negative symptoms usually persist. Because the effectiveness of different antipsychotics is relatively similar, choice of therapy is based primarily on patient comorbidities and the adverse effect profile. Typical or first-generation antipsychotic agents have a higher risk for extrapyramidal symptoms (parkinsonism, akathisia), tardive dyskinesia, and hyperprolactinemia than do second-generation or atypical antipsychotic agents ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gm_t57",
"wrapId":"16",
"children":[
"Table 57"
]
}
]
},
")"
]
},
". Newer antipsychotic agents may cause less sedation and fewer anticholinergic side effects but carry an increased risk for weight gain and metabolic syndrome (particularly olanzapine and quetiapine). Clozapine may be particularly effective for refractory schizophrenia but is associated with significant adverse effects, including agranulocytosis. Close monitoring for common adverse effects is extremely important with use of any antipsychotic agent."
]
},
{
"type":"inline-wrap",
"wrapId":"16",
"contentIds":[
"mk19_a_gm_t57"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"efc15c",
"children":[
"Mortality is significantly increased in patients with schizophrenia because of concomitant cardiovascular disease, behavioral disorders, and substance use; approximately 5% of patients with schizophrenia die by suicide."
]
},
{
"type":"keypoint",
"hlId":"ada673",
"children":[
"Antipsychotic medications are effective at controlling positive symptoms of schizophrenia, but some negative symptoms usually persist; choice of therapy is based primarily on patient comorbidities and adverse effect profile."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_10",
"title":{
"__html":"Attention-Deficit/Hyperactivity Disorder"
},
"titleNode":{
"type":"section-title",
"hlId":"ffdf2b",
"children":[
"Attention-Deficit/Hyperactivity Disorder"
]
},
"children":[
{
"type":"p",
"hlId":"f86c82",
"children":[
"Attention-deficit/hyperactivity disorder is characterized by persistent inattention and/or hyperactivity-impulsivity that disrupts functioning or development. Symptoms must interfere with at least two different settings (e.g., home and work), and some must have been present since before 12 years of age. This disorder is most frequently recognized in childhood, but diagnosis may be delayed until adulthood. Most patients diagnosed early in life continue to meet diagnostic criteria as adults. Common manifestations in adults include inattention, disorganization, distractibility, emotional dysregulation, and restlessness. The diagnosis is clinical, and rating scales may be useful. Anxiety, mood, and substance use disorders should be considered in the differential diagnosis but may exist concurrently."
]
},
{
"type":"p",
"hlId":"2569eb",
"children":[
"Pharmacologic therapy is similar in adults and children, with stimulants (methylphenidate, amphetamine) as first-line therapy. Close monitoring for cardiovascular side effects (hypertension, arrhythmia) is necessary. Given the potential for abuse, these drugs should not be prescribed to patients with a history of substance use disorder; atomoxetine may be preferred in such patients. Bupropion and tricyclic antidepressants are also beneficial in patients with contraindications to stimulants or with concurrent depression. CBT is beneficial alone or in combination with pharmacotherapy for improving function."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"f52526",
"children":[
"Stimulants should not be prescribed to patients with attention-deficit/hyperactivity disorder and a history of substance use disorder; atomoxetine may be preferred in such patients."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_11",
"title":{
"__html":"Autism Spectrum Disorder"
},
"titleNode":{
"type":"section-title",
"hlId":"4548be",
"children":[
"Autism Spectrum Disorder"
]
},
"children":[
{
"type":"p",
"hlId":"d614f7",
"children":[
"Autism spectrum disorder is a heterogeneous group of developmental disorders that feature repetitive behaviors and significant difficulties in communication and social interaction. Pathogenesis remains uncertain but is most likely genetic. Symptoms must be present since childhood to make the diagnosis, but symptoms may be masked until adulthood. Half of patients have intellectual disability, and many have concurrent seizure and sleep disorders. Early intervention with behavioral and educational support improves long-term functioning. Complementary therapies, such as specialized diets and music therapy, are also used but lack evidence of efficacy. Pharmacotherapy is reserved for targeted symptoms, such as melatonin for sleep disturbance. Even with intervention, most patients require lifelong assistance with functioning."
]
},
{
"type":"p",
"hlId":"e20dce",
"children":[
"Clinicians should understand each patient's ideal communication methods and allow extra time for explanation of procedures. Caregivers should be incorporated into health care visits, and consistency in the health care team can mitigate confusion and anxiety. Medical causes of acute behavioral changes should always be considered."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gm_s9_12",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"A new indication for esketamine nasal spray (Spravato). Med Lett Drugs Ther. 2020;62:151. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32960869",
"target":"_blank"
},
"children":[
"PMID: 32960869"
]
}
]
},
{
"type":"reference",
"children":[
"American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/14747245",
"target":"_blank"
},
"children":[
"PMID: 14747245"
]
},
" doi:10.2337/diacare.27.2.596"
]
},
{
"type":"reference",
"children":[
"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed: DSM-5. Arlington, VA: American Psychiatric Association; 2013."
]
},
{
"type":"reference",
"children":[
"Boyd JE, Lanius RA, McKinnon MC. Mindfulness-based treatments for posttraumatic stress disorder: a review of the treatment literature and neurobiological evidence. J Psychiatry Neurosci. 2017;42:170021. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28968198",
"target":"_blank"
},
"children":[
"PMID: 28968198"
]
},
" doi:10.1503/jpn.170021"
]
},
{
"type":"reference",
"children":[
"Brockmeyer T, Friederich HC, Schmidt U. Advances in the treatment of anorexia nervosa: a review of established and emerging interventions. Psychol Med. 2018;48:1228-56. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28889819",
"target":"_blank"
},
"children":[
"PMID: 28889819"
]
},
" doi:10.1017/S0033291717002604"
]
},
{
"type":"reference",
"children":[
"Brownley KA, Berkman ND, Peat CM, et al. Binge-eating disorder in adults: a systematic review and meta-analysis. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M15-2455",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2016;165:409-20. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27367316",
"target":"_blank"
},
"children":[
"PMID: 27367316"
]
}
]
},
{
"type":"reference",
"children":[
"Carvalho AF, Firth J, Vieta E. Bipolar disorder. N Engl J Med. 2020;383:58-66. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32609982",
"target":"_blank"
},
"children":[
"PMID: 32609982"
]
},
" doi:10.1056/NEJMra1906193"
]
},
{
"type":"reference",
"children":[
"Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020;71:306-33. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31314133",
"target":"_blank"
},
"children":[
"PMID: 31314133"
]
},
" doi:10.1002/hep.30866"
]
},
{
"type":"reference",
"children":[
"Craske MG, Stein MB. Anxiety. Lancet. 2016;388:3048-59. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27349358",
"target":"_blank"
},
"children":[
"PMID: 27349358"
]
},
" doi:10.1016/S0140-6736(16)30381-6"
]
},
{
"type":"reference",
"children":[
"Curry SJ, Krist AH, Owens DK, et al; US Preventive Services Task Force. Interventions to prevent perinatal depression: US Preventive Services Task Force recommendation statement. JAMA. 2019;321:580-7. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30747971",
"target":"_blank"
},
"children":[
"PMID: 30747971"
]
},
" doi:10.1001/jama.2019.0007"
]
},
{
"type":"reference",
"children":[
"Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75:139-48. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29282469",
"target":"_blank"
},
"children":[
"PMID: 29282469"
]
},
" doi:10.1001/jamapsychiatry.2017.3739"
]
},
{
"type":"reference",
"children":[
"DeMartini J, Patel G, Fancher TL. Generalized anxiety disorder. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/AITC201904020",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2019;170:ITC49-64. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30934083",
"target":"_blank"
},
"children":[
"PMID: 30934083"
]
}
]
},
{
"type":"reference",
"children":[
"Dickstein LP, Franco KN, Rome ES, et al. Recognizing, managing medical consequences of eating disorders in primary care. Cleve Clin J Med. 2014;81:255-63. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/24692444",
"target":"_blank"
},
"children":[
"PMID: 24692444"
]
},
" doi:10.3949/ccjm.81a.12132"
]
},
{
"type":"reference",
"children":[
"Edelman EJ, Fiellin DA. In the clinic. Alcohol use. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/AITC201601050",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2016;164:ITC1-16. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26747315",
"target":"_blank"
},
"children":[
"PMID: 26747315"
]
}
]
},
{
"type":"reference",
"children":[
"Gregory KD, Chelmow D, Nelson HD, et al; Women's Preventive Services Initiative. Screening for anxiety in adolescent and adult women: a recommendation from the Women's Preventive Services Initiative. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M20-0580",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2020;173:48-56. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32510990",
"target":"_blank"
},
"children":[
"PMID: 32510990"
]
}
]
},
{
"type":"reference",
"children":[
"Krist AH, Davidson KW, Mangione CM, et al; US Preventive Services Task Force. Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. JAMA. 2021;325:265-279. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33464343",
"target":"_blank"
},
"children":[
"PMID: 33464343"
]
},
" doi:10.1001/jama.2020.25019"
]
},
{
"type":"reference",
"children":[
"Krist AH, Davidson KW, Mangione CM, et al; US Preventive Services Task Force. Screening for unhealthy drug use: US Preventive Services Task Force recommendation statement. JAMA. 2020;323:2301-9. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32515821",
"target":"_blank"
},
"children":[
"PMID: 32515821"
]
},
" doi:10.1001/jama.2020.8020"
]
},
{
"type":"reference",
"children":[
"Leone FT, Zhang Y, Evers-Casey S, et al. Initiating pharmacologic treatment in tobacco-dependent adults. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;202(2):e5-e31. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32663106",
"target":"_blank"
},
"children":[
"PMID: 32663106"
]
},
" doi:10.1164/rccm.202005-1982ST"
]
},
{
"type":"reference",
"children":[
"Lieberman JA, First MB. Psychotic disorders. N Engl J Med. 2018;379:270-80. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30021088",
"target":"_blank"
},
"children":[
"PMID: 30021088"
]
},
" doi:10.1056/NEJMra1801490"
]
},
{
"type":"reference",
"children":[
"Lindson N, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2019;4:CD013308. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30997928",
"target":"_blank"
},
"children":[
"PMID: 30997928"
]
},
" doi:10.1002/14651858.CD013308"
]
},
{
"type":"reference",
"children":[
"Lindson-Hawley N, Banting M, West R, et al. Gradual versus abrupt smoking cessation: a randomized, controlled noninferiority trial. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M14-2805",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2016;164:585-92. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26975007",
"target":"_blank"
},
"children":[
"PMID: 26975007"
]
}
]
},
{
"type":"reference",
"children":[
"Mitchell JE, Peterson CB. Anorexia nervosa. N Engl J Med. 2020;382:1343-51. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32242359",
"target":"_blank"
},
"children":[
"PMID: 32242359"
]
},
" doi:10.1056/NEJMcp1803175"
]
},
{
"type":"reference",
"children":[
"O’Neil ME, Nugent SM, Morasco BJ, et al. Benefits and harms of plant-based cannabis for posttraumatic stress disorder: a systematic review. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M17-0477",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2017;167:332-40. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28806794",
"target":"_blank"
},
"children":[
"PMID: 28806794"
]
}
]
},
{
"type":"reference",
"children":[
"Pace CA, Samet JH. In the clinic. Substance use disorders. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/AITC201604050",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2016;164:ITC49-64. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27043992",
"target":"_blank"
},
"children":[
"PMID: 27043992"
]
}
]
},
{
"type":"reference",
"children":[
"Park LT, Zarate CA Jr. Depression in the primary care setting. N Engl J Med. 2019;380:559-68. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30726688",
"target":"_blank"
},
"children":[
"PMID: 30726688"
]
},
" doi:10.1056/NEJMcp1712493"
]
},
{
"type":"reference",
"children":[
"Patel MS, Steinberg MB. In the clinic. Smoking cessation. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/AITC201603010",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2016;164:ITC33-48. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26926702",
"target":"_blank"
},
"children":[
"PMID: 26926702"
]
}
]
},
{
"type":"reference",
"children":[
"Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175:86-90. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29301420",
"target":"_blank"
},
"children":[
"PMID: 29301420"
]
},
" doi:10.1176/appi.ajp.2017.1750101"
]
},
{
"type":"reference",
"children":[
"Schuckit MA. Treatment of opioid-use disorders. N Engl J Med. 2016;375:357-68. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27464203",
"target":"_blank"
},
"children":[
"PMID: 27464203"
]
},
" doi:10.1056/NEJMra1604339"
]
},
{
"type":"reference",
"children":[
"Shalev A, Liberzon I, Marmar C. Post-traumatic stress disorder. N Engl J Med. 2017;376:2459-69. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28636846",
"target":"_blank"
},
"children":[
"PMID: 28636846"
]
},
" doi:10.1056/NEJMra1612499"
]
},
{
"type":"reference",
"children":[
"Stoffers JM, Lieb K. Pharmacotherapy for borderline personality disorder—current evidence and recent trends. Curr Psychiatry Rep. 2015;17:534. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/25413640",
"target":"_blank"
},
"children":[
"PMID: 25413640"
]
},
" doi:10.1007/s11920-014-0534-0"
]
},
{
"type":"reference",
"children":[
"Williams AR, Hill KP. Care of the patient using cannabis. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/AITC202011030",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2020;173:ITC65-80. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33137270",
"target":"_blank"
},
"children":[
"PMID: 33137270"
]
}
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_a_gm_t45":{
"id":"mk19_a_gm_t45",
"number":45,
"bookId":"gm",
"title":{
"__html":"Factors That Increase Risk for Suicide"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"3885dc",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 45. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gm_t45"
}
]
},
"Factors That Increase Risk for Suicide"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b1a9aa",
"class":"cell txt l",
"children":[
"Chronic suicidal ideation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"192828",
"class":"cell txt l",
"children":[
"Major mental illness or personality disorder"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1a8601",
"class":"cell txt l",
"children":[
"History of prior suicide attempts"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bdcceb",
"class":"cell txt l",
"children":[
"History of substance use disorder"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fce98a",
"class":"cell txt l",
"children":[
"Chronic pain"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a3dee6",
"class":"cell txt l",
"children":[
"Chronic medical condition"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0aa496",
"class":"cell txt l",
"children":[
"Limited coping skills"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"403e66",
"class":"cell txt l",
"children":[
"Unstable or turbulent psychosocial status (e.g., unstable housing, erratic relationships, marginal employment)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"98bc59",
"class":"cell txt l",
"children":[
"Limited ability to identify reasons for living"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"Information from Sall J, Brenner L, Millikan Bell AM, et al. Assessment and management of patients at risk for suicide: synopsis of the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guidelines. Ann Intern Med. 2019;171:343-53. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31450237",
"target":"_blank"
},
"children":[
"PMID: 31450237"
]
}
]
]
},
"mk19_a_gm_t46":{
"id":"mk19_a_gm_t46",
"number":46,
"bookId":"gm",
"title":{
"__html":"Symptom Criteria for Diagnosis of Common Mood Disorders"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"57a793",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 46. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gm_t46"
}
]
},
"Symptom Criteria for Diagnosis of Common Mood Disorders"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"77ae23",
"class":"col hd l",
"children":[
"Major Depressive Disorder"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"df682c",
"class":"cell txt l",
"children":[
"Five or more of the symptoms listed below (at least one of the symptoms must be depressed mood or anhedonia) nearly every day or all of the time during the same 2-wk period:"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f09f7c",
"class":"cell txt li",
"children":[
"Depressed mood"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e258b1",
"class":"cell txt li",
"children":[
"Anhedonia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bf09d9",
"class":"cell txt li",
"children":[
"Insomnia/hypersomnia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5c11c7",
"class":"cell txt li",
"children":[
"Weight loss/gain, appetite increase/decrease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fb5c7a",
"class":"cell txt li",
"children":[
"Fatigue/decreased energy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c5dd62",
"class":"cell txt li",
"children":[
"Psychomotor agitation/retardation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8980c7",
"class":"cell txt li",
"children":[
"Decreased concentration"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9b1093",
"class":"cell txt li",
"children":[
"Feelings of worthlessness or excessive/inappropriate guilt"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ff67ad",
"class":"cell txt li",
"children":[
"Recurrent thoughts of death, suicidal ideation, or suicide attempt"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"64c973",
"class":"col hd l",
"children":[
"Persistent Depressive Disorder"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0f3119",
"class":"cell txt l",
"children":[
"Depressed mood most of the time for 2 y plus two of the following:"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"edc656",
"class":"cell txt li",
"children":[
"Appetite change"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"433f00",
"class":"cell txt li",
"children":[
"Fatigue or low energy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fb6d6d",
"class":"cell txt li",
"children":[
"Decreased self-esteem"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"913c99",
"class":"cell txt li",
"children":[
"Insomnia or hypersomnia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ef2ba9",
"class":"cell txt li",
"children":[
"Poor concentration"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e5810",
"class":"cell txt li",
"children":[
"Hopelessness"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9c839b",
"class":"col hd l",
"children":[
"Seasonal Affective Disorder"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"65bcdc",
"class":"cell txt l",
"children":[
"Symptoms of major depressive disorder, mania, or hypomania occurring in autumn/winter and remitting in the spring"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0c505d",
"class":"col hd l",
"children":[
"Premenstrual Dysphoric Disorder"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a58aef",
"class":"cell txt l",
"children":[
"At least one primary symptom (mood swings, irritability or anger, hopelessness or depressed mood, anxiety) plus four additional symptoms:"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"56af7f",
"class":"cell txt li",
"children":[
"Mood swings"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b63128",
"class":"cell txt li",
"children":[
"Irritability or anger"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"64367c",
"class":"cell txt li",
"children":[
"Hopelessness or depressed mood"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"66ab81",
"class":"cell txt li",
"children":[
"Anxiety"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"edc656",
"class":"cell txt li",
"children":[
"Appetite change"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e258b1",
"class":"cell txt li",
"children":[
"Anhedonia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b5ff1b",
"class":"cell txt li",
"children":[
"Fatigue"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1f539b",
"class":"cell txt li",
"children":[
"Difficulty concentrating"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ea6b03",
"class":"cell txt li",
"children":[
"Feelings of loss of control"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6c73a4",
"class":"cell txt li",
"children":[
"Sleep disturbance"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8253a5",
"class":"cell txt li",
"children":[
"Physical symptoms: breast pain, bloating, myalgias, weight gain"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"40efb1",
"class":"col hd l",
"children":[
"Peripartum Depression"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"86c0c8",
"class":"cell txt l",
"children":[
"Symptoms of major depressive disorder occurring during or within 4 wk after pregnancy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"58c326",
"class":"col hd l",
"children":[
"Persistent Complex Bereavement Disorder"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b7ddb8",
"class":"cell txt l",
"children":[
"Labile emotions, sadness, loneliness, and fleeting hallucinations for >12 mo"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b29a9f",
"class":"cell txt l",
"children":[
"Intense longing for or preoccupation with the deceased"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9841e8",
"class":"cell txt l",
"children":[
"Feelings of emptiness, inability to live"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7feb48",
"class":"col hd l",
"children":[
"Bipolar Disorder 1/2"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ff2e9b",
"class":"cell txt l",
"children":[
"Symptoms of depression plus at least one episode of mania/hypomania. Mania requires at least 7 consecutive days of severe, abnormally expansive, euphoric, or irritable mood plus at least three of the below additional symptoms (four if the patient reports irritable mood only). Hypomania requires at least 4 consecutive days of symptoms without severe impairment based on presence of symptoms listed below."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8fb09b",
"class":"cell txt li",
"children":[
"Irritable, expansive/elevated mood"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bbda2c",
"class":"cell txt li",
"children":[
"Inflated self-esteem"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5726f7",
"class":"cell txt li",
"children":[
"Increased talkativeness"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"207d02",
"class":"cell txt li",
"children":[
"Flight of ideas"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5fc6fc",
"class":"cell txt li",
"children":[
"Distractibility"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e964ec",
"class":"cell txt li",
"children":[
"Decreased need for sleep"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"199d9c",
"class":"cell txt li",
"children":[
"Increased goal-directed activity"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ee1f73",
"class":"cell txt li",
"children":[
"Excessive risk-taking behavior"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_a_gm_t47":{
"id":"mk19_a_gm_t47",
"number":47,
"bookId":"gm",
"title":{
"__html":"Common Psychological Interventions to Treat Depression"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"9e0c14",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 47. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gm_t47"
}
]
},
"Common Psychological Interventions to Treat Depression"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c143a2",
"class":"col hd l",
"children":[
"Intervention"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b5a7ad",
"class":"col hd l",
"children":[
"Description"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26d440",
"class":"cell txt l",
"children":[
"Acceptance and commitment therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6d0c98",
"class":"cell txt l",
"children":[
"Uses mindfulness techniques to overcome negative thoughts and accept difficulties"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"828c1d",
"class":"cell txt l",
"children":[
"Cognitive therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b53c0e",
"class":"cell txt l",
"children":[
"Helps patients correct false self-beliefs and negative thoughts"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab3aa7",
"class":"cell txt l",
"children":[
"Cognitive behavioral therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0900b7",
"class":"cell txt l",
"children":[
"Includes a behavioral component in cognitive therapy, such as activity scheduling and homework"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cb17db",
"class":"cell txt l",
"children":[
"Interpersonal therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9dc4eb",
"class":"cell txt l",
"children":[
"Focuses on relationships and how to address issues related to them"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"402e15",
"class":"cell txt l",
"children":[
"Psychodynamic therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"00f61c",
"class":"cell txt l",
"children":[
"Focuses on conscious and unconscious feelings and experiences"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3b8b22",
"class":"cell txt l",
"children":[
"Third-wave cognitive behavioral therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e0944",
"class":"cell txt l",
"children":[
"Targets thought processes to help persons with awareness and acceptance"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"Reproduced with permission from Qaseem A, Barry MJ, Kansagara D; Clinical Guidelines Committee of the American College of Physicians. Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American College of Physicians. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M15-2570",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2016;164:351. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26857948",
"target":"_blank"
},
"children":[
"PMID: 26857948"
]
},
". © 2016, American College of Physicians."
]
]
},
"mk19_a_gm_t48":{
"id":"mk19_a_gm_t48",
"number":48,
"bookId":"gm",
"title":{
"__html":"Dosages and Comparative Adverse Effects of Second-Generation Antidepressants"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"8507f9",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 48. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gm_t48"
}
]
},
"Dosages and Comparative Adverse Effects of Second-Generation Antidepressants"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5db77f",
"class":"col hd l",
"children":[
"Drug"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b18700",
"class":"col hd l",
"children":[
"Dosage (mg/d)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"743451",
"class":"col hd l",
"children":[
"Comparative or Drug-Specific Adverse Effects",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"84f8f5",
"class":"col hd l",
"children":[
"Selective Serotonin Reuptake Inhibitors (SSRIs)"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9f9256",
"class":"cell txt l",
"children":[
"Citalopram"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"23bd4c",
"class":"cell txt l",
"children":[
"20-40"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2c9c43",
"class":"cell txt l",
"children":[
"Possible increased risk for QT interval prolongation and torsades de pointes (dosages >40 mg/d)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"433b69",
"class":"cell txt l",
"children":[
"Escitalopram"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0789c0",
"class":"cell txt l",
"children":[
"10-20"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"be4ea5",
"class":"cell txt l",
"children":[
"QT prolongation (less than with citalopram)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a0f638",
"class":"cell txt l",
"children":[
"Fluoxetine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9dbc93",
"class":"cell txt l",
"children":[
"10-80"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0f7595",
"class":"cell txt l",
"children":[
"Lowest rates of discontinuation syndrome compared with other SSRIs"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3c1e43",
"class":"cell txt l",
"children":[
"Fluvoxamine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7e9c0d",
"class":"cell txt l",
"children":[
"40-120"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d4cd0d",
"class":"cell txt l",
"children":[
"NA"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"00016c",
"class":"cell txt l",
"children":[
"Paroxetine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7249af",
"class":"cell txt l",
"children":[
"20-60"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"802463",
"class":"cell txt l",
"children":[
"Highest rates of sexual dysfunction among SSRIs; higher rates of weight gain; highest rates of discontinuation syndrome"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a4b119",
"class":"cell txt l",
"children":[
"Sertraline"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"543074",
"class":"cell txt l",
"children":[
"50-200"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"55521e",
"class":"cell txt l",
"children":[
"Higher incidence of diarrhea"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"2599bb",
"class":"col hd l",
"children":[
"Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"184c78",
"class":"cell txt l",
"children":[
"Venlafaxine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"815d82",
"class":"cell txt l",
"children":[
"75-375"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bdd805",
"class":"cell txt l",
"children":[
"Higher rates of nausea and vomiting; higher rates of discontinuation due to adverse events than with SSRIs as a class; highest rates of discontinuation syndrome"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ce5afc",
"class":"cell txt l",
"children":[
"Venlafaxine XR"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"68fd84",
"class":"cell txt l",
"children":[
"75-225"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f55714",
"class":"cell txt l",
"children":[
"Desvenlafaxine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2e2327",
"class":"cell txt l",
"children":[
"50-100"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ec1f0e",
"class":"cell txt l",
"children":[
"Same as venlafaxine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"634741",
"class":"cell txt l",
"children":[
"Duloxetine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d6da9d",
"class":"cell txt l",
"children":[
"60-120"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3aec05",
"class":"cell txt l",
"children":[
"Same as venlafaxine, but lower rates of adverse events and discontinuation syndrome than with other SNRIs"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"9f8060",
"class":"col hd l",
"children":[
"Serotonin Modulators"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"60627c",
"class":"cell txt l",
"children":[
"Nefazodone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f10e31",
"class":"cell txt l",
"children":[
"200-600"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d4cd0d",
"class":"cell txt l",
"children":[
"NA"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"4a27ec",
"class":"col hd l",
"children":[
"Atypical Antidepressants"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4024de",
"class":"cell txt l",
"children":[
"Bupropion"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c3bda3",
"class":"cell txt l",
"children":[
"200-450"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"133e01",
"class":"cell txt l",
"children":[
"Lower rate of sexual adverse events than with escitalopram, fluoxetine, paroxetine, and sertraline"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"041150",
"class":"cell txt l",
"children":[
"Bupropion SR"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10f00d",
"class":"cell txt l",
"children":[
"150-400"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"NA = not available; SR = sustained release; XR = extended release."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Common adverse effects associated with second-generation antidepressants include constipation, diarrhea, dizziness, headache, insomnia, nausea, sexual adverse events, and somnolence."
],
[
"Adapted with permission from Qaseem A, Barry MJ, Kansagara D; Clinical Guidelines Committee of the American College of Physicians. Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American College of Physicians. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M15-2570",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2016;164:350-9. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26857948",
"target":"_blank"
},
"children":[
"PMID: 26857948"
]
},
". ©2016, American College of Physicians."
]
]
},
"mk19_a_gm_t49":{
"id":"mk19_a_gm_t49",
"number":49,
"bookId":"gm",
"title":{
"__html":"Pharmacotherapy for Generalized Anxiety Disorder"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"70f08c",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 49. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gm_t49"
}
]
},
"Pharmacotherapy for Generalized Anxiety Disorder"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c72cb5",
"class":"col hd l",
"children":[
"Class of Agent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"01ad30",
"class":"col hd l",
"children":[
"Specific Agent, Therapeutic Dose"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fb64ae",
"class":"col hd l",
"children":[
"Adverse Effects and Notes"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7945c8",
"class":"cell txt l",
"children":[
"First-line medications: SSRIs and SNRIs"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"677077",
"class":"cell txt l",
"children":[
"As a class: nausea, diarrhea, decreased appetite, restlessness, insomnia, somnolence, impaired sexual function, and hyponatremia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b98a0f",
"class":"cell txt li",
"children":[
"SSRI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f8967d",
"class":"cell txt l",
"children":[
"Escitalopram, 10-20 mg/d"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b09cd",
"class":"cell txt l",
"children":[
"QT prolongation"
]
},
" ",
{
"type":"p",
"hlId":"d45356",
"class":"cell txt l",
"children":[
"10 mg/d is the maximum dose recommended for elderly adults and those with hepatic impairment"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b98a0f",
"class":"cell txt li",
"children":[
"SSRI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4b8353",
"class":"cell txt l",
"children":[
"Paroxetine, 20-60 mg/d"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"556062",
"class":"cell txt l",
"children":[
"More sexual dysfunction, weight gain, and sedation; discontinuation syndrome not uncommon"
]
},
" ",
{
"type":"p",
"hlId":"043ba7",
"class":"cell txt l",
"children":[
"Increased drug interactions, including strong CYP2D6 inhibition"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b98a0f",
"class":"cell txt li",
"children":[
"SSRI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"588e57",
"class":"cell txt l",
"children":[
"Sertraline, 50-200 mg/d"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"449e55",
"class":"cell txt l",
"children":[
"Higher incidence of gastrointestinal distress"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2dcca5",
"class":"cell txt li",
"children":[
"SNRI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1b3b40",
"class":"cell txt l",
"children":[
"Duloxetine, 60-120 mg/d"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"355a4b",
"class":"cell txt l",
"children":[
"Gastrointestinal distress (less than with venlafaxine)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2dcca5",
"class":"cell txt li",
"children":[
"SNRI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"90f02f",
"class":"cell txt l",
"children":[
"Venlafaxine extended-release, 75-225 mg/d"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ecb1e9",
"class":"cell txt l",
"children":[
"Higher incidence of gastrointestinal distress; increased blood pressure"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9de2f7",
"class":"cell txt l",
"children":[
"Second-line medications"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"faa566",
"class":"cell txt li",
"children":[
"Azapirones"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fba640",
"class":"cell txt l",
"children":[
"Buspirone, 15-30 mg/d"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"057883",
"class":"cell txt l",
"children":[
"Ineffective for comorbid disorders; dizziness, drowsiness"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"521c0d",
"class":"cell txt li",
"children":[
"Benzodiazepines"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a48322",
"class":"cell txt l",
"children":[
"Alprazolam, 0.25-1 mg/d; lorazepam, 0.5-2 mg/d"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"96f95c",
"class":"cell txt l",
"children":[
"As a class: falls, memory impairment, risk for dependence"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b2adee",
"class":"cell txt li",
"children":[
"Anticonvulsant"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"05394a",
"class":"cell txt l",
"children":[
"Pregabalin, 150-600 mg/d"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e2611d",
"class":"cell txt l",
"children":[
"Sedation, dizziness, peripheral edema"
]
},
" ",
{
"type":"p",
"hlId":"2fcdab",
"class":"cell txt l",
"children":[
"Used as an adjuvant to first-line medications"
]
},
" ",
{
"type":"p",
"hlId":"f5254b",
"class":"cell txt l",
"children":[
"Use with caution in patients with renal impairment"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"09b28c",
"class":"cell txt li",
"children":[
"Antihistamine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e6114",
"class":"cell txt l",
"children":[
"Hydroxyzine, 50-100 mg 4 times daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"39a178",
"class":"cell txt l",
"children":[
"Sedation, dry mouth, confusion, and urine retention"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor."
],
[
"Adapted with permission from DeMartini J, Patel G, Fancher TL. Generalized anxiety disorder. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/AITC201904020",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2019;170:ITC49-64. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30934083",
"target":"_blank"
},
"children":[
"PMID: 30934083"
]
},
". © 2019, American College of Physicians."
]
]
},
"mk19_a_gm_t50":{
"id":"mk19_a_gm_t50",
"number":50,
"bookId":"gm",
"title":{
"__html":"Tobacco Cessation: The 5 A's"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"cb8e6a",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 50. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gm_t50"
}
]
},
"Tobacco Cessation: The 5 A's"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"51dca1",
"class":"cell txt l",
"children":[
"ASK about tobacco use at every encounter"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"67aca6",
"class":"cell txt li",
"children":[
"Identify and document tobacco use"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"abae14",
"class":"cell txt li",
"children":[
"Consider a systematic process (e.g., asking about tobacco use when taking vital signs)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"401dc8",
"class":"cell txt l",
"children":[
"ADVISE patients to quit tobacco use"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3bb2d3",
"class":"cell txt li",
"children":[
"Strong, clear, personalized message"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6c14dc",
"class":"cell txt l",
"children":[
"ASSESS willingness to quit"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"67d0a7",
"class":"cell txt li",
"children":[
"Not everyone is ready to try to quit"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0d1896",
"class":"cell txt li",
"children":[
"If not ready, offer motivational counseling"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"97b6fc",
"class":"cell txt l",
"children":[
"ASSIST in quitting"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"60f17b",
"class":"cell txt li",
"children":[
"Set a quit date"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1b8de9",
"class":"cell txt li",
"children":[
"Behavioral changes: alternatives, skills"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d5b161",
"class":"cell txt li",
"children":[
"Pharmacotherapy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"43ccf9",
"class":"cell txt li",
"children":[
"Support: environment, triggers"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7635cd",
"class":"cell txt l",
"children":[
"ARRANGE follow-up"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4815d9",
"class":"cell txt li",
"children":[
"In person, telephone, electronic"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c3bbc8",
"class":"cell txt li",
"children":[
"Monitor progress, side effects, withdrawal"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"Adapted from Fiore MC, Jaen C, Baker T, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services. 2008. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/books/NBK63952/",
"target":"_blank"
},
"children":[
"www.ncbi.nlm.nih.gov/books/NBK63952/"
]
},
"."
]
]
},
"mk19_a_gm_t51":{
"id":"mk19_a_gm_t51",
"number":51,
"bookId":"gm",
"title":{
"__html":"Approved Medications for Treatment of Tobacco Use"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"55bb32",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 51. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gm_t51"
}
]
},
"Approved Medications for Treatment of Tobacco Use"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"deb105",
"class":"col hd l",
"children":[
"Product"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f7b2ce",
"class":"col hd l",
"children":[
"Advantages"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"90843c",
"class":"col hd l",
"children":[
"Disadvantages"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6b0217",
"class":"col hd l",
"children":[
"Precautions"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"017e8f",
"class":"col hd l",
"children":[
"Side Effects"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"5"
},
"children":[
" ",
{
"type":"p",
"hlId":"828139",
"class":"col hd l",
"children":[
"Long-Acting"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"733425",
"class":"cell txt l",
"children":[
"Nicotine patch"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"732eaf",
"class":"cell txt l",
"children":[
"Place and forget; available over the counter; can decrease morning cravings if worn at night"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"723bb9",
"class":"cell txt l",
"children":[
"Passive—no action to take when craving occurs"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9f45f7",
"class":"cell txt l",
"children":[
"Use with caution within 2 wk of a cardiac event",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"af6e7a",
"class":"cell txt l",
"children":[
"Skin reaction (50% of patients), vivid dreams or sleep disturbances"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"631104",
"class":"cell txt l",
"children":[
"Bupropion SR (twice daily) and XL (once daily)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a22e05",
"class":"cell txt l",
"children":[
"Less weight gain; antidepressant benefit"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f37999",
"class":"cell txt l",
"children":[
"Side effects not uncommon"
]
},
" ",
{
"type":"p",
"hlId":"0494e3",
"class":"cell txt l",
"children":[
"Passive—no action to take with cravings; prescription required"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7134f1",
"class":"cell txt l",
"children":[
"Do not use in patients with seizure disorders, current use of bupropion or MAO inhibitors, electrolyte abnormalities, or eating disorders; monitor blood pressure"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"97fa3e",
"class":"cell txt l",
"children":[
"Insomnia (40%), dry mouth, headache, anxiety, rash"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"301835",
"class":"cell txt l",
"children":[
"Varenicline"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f06925",
"class":"cell txt l",
"children":[
"Reduces withdrawal; may prevent relapse"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"16a8b1",
"class":"cell txt l",
"children":[
"Passive—no action to take with cravings"
]
},
" ",
{
"type":"p",
"hlId":"2fbea7",
"class":"cell txt l",
"children":[
"Prescription required"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"df399e",
"class":"cell txt l",
"children":[
"Avoid with severe kidney disease; evaluate for mental illness and monitor mood"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1edf2c",
"class":"cell txt l",
"children":[
"Nausea (30%), insomnia, vivid dreams/nightmares"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"5"
},
"children":[
" ",
{
"type":"p",
"hlId":"2d52e1",
"class":"col hd l",
"children":[
"Short-Acting"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"249766",
"class":"cell txt l",
"children":[
"Nicotine gum"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a8ec9a",
"class":"cell txt l",
"children":[
"Use as needed; can self-dose; available over the counter"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"238b2e",
"class":"cell txt l",
"children":[
"Difficult to chew, poor taste"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c83c5a",
"class":"cell txt l",
"children":[
"Proper use is “chew and park (at cheek)”"
]
},
" ",
{
"type":"p",
"hlId":"9f45f7",
"class":"cell txt l",
"children":[
"Use with caution within 2 wk of a cardiac event",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"54dbed",
"class":"cell txt l",
"children":[
"Jaw pain; nausea if swallowing saliva"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1e4ff",
"class":"cell txt l",
"children":[
"Nicotine inhaler"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0bd351",
"class":"cell txt l",
"children":[
"Use as needed; mimics hand-mouth behavior"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"98dcf1",
"class":"cell txt l",
"children":[
"Costly; visible; requires prescription"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6a998d",
"class":"cell txt l",
"children":[
"Caution within 2 wk of a cardiac event",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2a2db6",
"class":"cell txt l",
"children":[
"Cough, throat irritation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f3d8db",
"class":"cell txt l",
"children":[
"Nicotine nasal spray"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a32b4e",
"class":"cell txt l",
"children":[
"Use as needed; rapid relief of symptoms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"98dcf1",
"class":"cell txt l",
"children":[
"Costly; visible; requires prescription"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"78295e",
"class":"cell txt l",
"children":[
"Use with caution in patients with asthma or nasal/sinus problems"
]
},
" ",
{
"type":"p",
"hlId":"9f45f7",
"class":"cell txt l",
"children":[
"Use with caution within 2 wk of a cardiac event",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"06a98d",
"class":"cell txt l",
"children":[
"Nasal irritation; possible dependence"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"082b84",
"class":"cell txt l",
"children":[
"Nicotine lozenge"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7caf3b",
"class":"cell txt l",
"children":[
"Ease of use; available over the counter; flexible dosing"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a238fd",
"class":"cell txt l",
"children":[
"Slightly more costly than gum"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b51ce3",
"class":"cell txt l",
"children":[
"Caution within 2 wk of cardiac event",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cb3ad6",
"class":"cell txt l",
"children":[
"Hiccups, nausea, heartburn"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"MAO = monoamine oxidase; SR = sustained release; XL = extended release."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Recent myocardial infarction, severe angina, or life-threatening arrhythmia."
],
[
"Adapted with permission from Patel MS, Steinberg MB. In the clinic. Smoking cessation. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/AITC201603010",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2016;164:ITC33-48. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26926702",
"target":"_blank"
},
"children":[
"PMID: 26926702"
]
},
". © 2016, American College of Physicians."
]
]
},
"mk19_a_gm_t52":{
"id":"mk19_a_gm_t52",
"number":52,
"bookId":"gm",
"title":{
"__html":"Alcohol Use Categories"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"d77166",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 52. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gm_t52"
}
]
},
"Alcohol Use Categories"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3adbdb",
"class":"col hd l",
"children":[
"Category"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b890b",
"class":"col hd l",
"children":[
"Definition"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"34ccc4",
"class":"col hd l",
"children":[
"Health Consequences"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1ad30c",
"class":"cell txt l",
"children":[
"Moderate- or lower-risk alcohol use"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d91e68",
"class":"cell txt l",
"children":[
"No more than four drinks on a single day or 14 drinks/wk for men; for men >65 years of age and women, no more than three drinks on a single day or seven drinks in a week"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a4fd1f",
"class":"cell txt l",
"children":[
"Uncommon"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e8dcd",
"class":"cell txt l",
"children":[
"Hazardous or at-risk drinking"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"427950",
"class":"cell txt l",
"children":[
"When thresholds for lower-risk alcohol use are exceeded"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4a9e6c",
"class":"cell txt l",
"children":[
"Increased risk for alcohol-related social and legal consequences"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1eb50a",
"class":"cell txt l",
"children":[
"Harmful alcohol use"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"112625",
"class":"cell txt l",
"children":[
"Pattern of drinking that causes health consequences"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2d9fd3",
"class":"cell txt l",
"children":[
"Alcohol use disorder"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a16339",
"class":"cell txt l",
"children":[
"When the individual meets at least 2 of the 11 DSM-5 criteria"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bf4f15",
"class":"cell txt l",
"children":[
"Patients with moderate to severe alcohol use disorder (more than three criteria met) may benefit from more intensive treatment"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_a_gm_t53":{
"id":"mk19_a_gm_t53",
"number":53,
"bookId":"gm",
"title":{
"__html":"Pharmacotherapy for Alcohol Use Disorder"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"ea0f75",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 53. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gm_t53"
}
]
},
"Pharmacotherapy for Alcohol Use Disorder"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"01d822",
"class":"col hd l",
"children":[
"Medication and Typical Dosage",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1b1583",
"class":"col hd l",
"children":[
"Indication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7a3d46",
"class":"col hd l",
"children":[
"Mechanism"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"017e8f",
"class":"col hd l",
"children":[
"Side Effects"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4c6f8",
"class":"col hd l",
"children":[
"Notes"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ce64a3",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Naltrexone"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"f2d464",
"class":"cell txt l",
"children":[
"Oral, 50-100 mg daily"
]
},
" ",
{
"type":"p",
"hlId":"814d6a",
"class":"cell txt l",
"children":[
"Injectable, 380 mg monthly"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c16435",
"class":"cell txt l",
"children":[
"Relapse prevention"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"246b42",
"class":"cell txt l",
"children":[
"Opioid antagonist that may reduce the subjective reward associated with alcohol use"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e38df",
"class":"cell txt l",
"children":[
"Nausea, indigestion, headache, fatigue"
]
},
" ",
{
"type":"p",
"hlId":"45feea",
"class":"cell txt l",
"children":[
"Depressive symptoms"
]
},
" ",
{
"type":"p",
"hlId":"20994b",
"class":"cell txt l",
"children":[
"Rarely, medication-associated hepatitis"
]
},
" ",
{
"type":"p",
"hlId":"cbb4a5",
"class":"cell txt l",
"children":[
"Potential for precipitated opioid withdrawal with opioid use"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d83ecc",
"class":"cell txt l",
"children":[
"Contraindicated with concurrent opioid use; offer with concomitant opioid use disorder",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" ",
{
"type":"p",
"hlId":"be7628",
"class":"cell txt l",
"children":[
"Avoid in patients with decompensated cirrhosis, acute hepatitis, or liver failure",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"; use with caution in patients with hepatitis or compensated cirrhosis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cb0d2c",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Acamprosate"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"befefb",
"class":"cell txt l",
"children":[
"666 mg three times daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c16435",
"class":"cell txt l",
"children":[
"Relapse prevention"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"702892",
"class":"cell txt l",
"children":[
"May antagonize glutamate-mediated neuronal hyperexcitability and reduce prolonged (but not acute) withdrawal symptoms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f9d3db",
"class":"cell txt l",
"children":[
"Diarrhea, nausea/vomiting, myalgia, rash, dizziness, palpitations"
]
},
" ",
{
"type":"p",
"hlId":"ec4f99",
"class":"cell txt l",
"children":[
"Rarely associated with kidney impairment"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10d2a2",
"class":"cell txt l",
"children":[
"Can be used in patients with alcohol-related liver disease"
]
},
" ",
{
"type":"p",
"hlId":"d5173d",
"class":"cell txt l",
"children":[
"Avoid in patients with severe kidney impairment (eGFR <30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"); second-line therapy in mild to moderate kidney impairment and requires reduced dosage",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" ",
{
"type":"p",
"hlId":"aea6ea",
"class":"cell txt l",
"children":[
"May be used with naltrexone"
]
},
" ",
{
"type":"p",
"hlId":"37d22c",
"class":"cell txt l",
"children":[
"Medication adherence may be challenging"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"905fb0",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Disulfiram"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"34eb87",
"class":"cell txt l",
"children":[
"250-500 mg daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3a9537",
"class":"cell txt l",
"children":[
"Prevention of drinking and relapse prevention"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ed192b",
"class":"cell txt l",
"children":[
"Aldehyde dehydrogenase inhibition results in acetaldehyde accumulation with alcohol use, leading to unpleasant symptoms (alcohol-disulfiram reaction)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f06cb",
"class":"cell txt l",
"children":[
"Drowsiness, rash"
]
},
" ",
{
"type":"p",
"hlId":"cbaa57",
"class":"cell txt l",
"children":[
"Rarely, medication-associated severe hepatotoxicity, optic neuritis, peripheral neuropathy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2f4bb5",
"class":"cell txt l",
"children":[
"Potential for many drug-drug interactions"
]
},
" ",
{
"type":"p",
"hlId":"19dc2c",
"class":"cell txt l",
"children":[
"Patient must be abstinent ≥12 h before medication administration"
]
},
" ",
{
"type":"p",
"hlId":"877ff7",
"class":"cell txt l",
"children":[
"Avoid in patients with hepatic impairment or cardiovascular disease"
]
},
" ",
{
"type":"p",
"hlId":"a09fb1",
"class":"cell txt l",
"children":[
"Most appropriate for patients with strong motivation to be abstinent and with support to promote medication adherence"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"eGFR = estimated glomerular filtration rate."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Naltrexone, disulfiram, and acamprosate are all FDA pregnancy category C (animal studies indicate potential fetal risk or have not been conducted, and no or insufficient human studies have been done; drugs in this category should be used in pregnant or lactating women only when potential benefits justify potential risk to the fetus or infant)."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Information from Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175:86-90. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29301420",
"target":"_blank"
},
"children":[
"PMID: 29301420"
]
},
" doi:10.1176/appi.ajp.2017.1750101"
],
[
"Adapted with permission from Edelman EJ, Fiellin DA. In the clinic. Alcohol use. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/AITC201601050",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2016;164:ITC10. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26747315",
"target":"_blank"
},
"children":[
"PMID: 26747315"
]
},
".. © 2016, American College of Physicians."
]
]
},
"mk19_a_gm_t54":{
"id":"mk19_a_gm_t54",
"number":54,
"bookId":"gm",
"title":{
"__html":"Pharmacotherapy for Alcohol Withdrawal"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"94b937",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 54. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gm_t54"
}
]
},
"Pharmacotherapy for Alcohol Withdrawal"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"353bd6",
"class":"col hd l",
"children":[
"Medication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1b1583",
"class":"col hd l",
"children":[
"Indication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"017e8f",
"class":"col hd l",
"children":[
"Side Effects"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4c6f8",
"class":"col hd l",
"children":[
"Notes"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"11f022",
"class":"cell txt l",
"children":[
"Benzodiazepines",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e5aa6",
"class":"cell txt l",
"children":[
"Treatment or prophylaxis for alcohol withdrawal syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"059569",
"class":"cell txt l",
"children":[
"Oversedation, paradoxical hyperactivity, depression, addictive potential"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c3040d",
"class":"cell txt l",
"children":[
"Caution in patients with respiratory or hepatic impairment"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8483f4",
"class":"cell txt l",
"children":[
"Dexmedetomidine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"14837f",
"class":"cell txt l",
"children":[
"Adjunctive treatment of severe alcohol withdrawal symptoms in an ICU setting"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"730680",
"class":"cell txt l",
"children":[
"Bradycardia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa089f",
"class":"cell txt l",
"children":[
"Clinical use increasing despite lack of evidence of clear benefit"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3b68f2",
"class":"cell txt l",
"children":[
"Gabapentin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e2845",
"class":"cell txt l",
"children":[
"Treatment of mild alcohol withdrawal symptoms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"39bb36",
"class":"cell txt l",
"children":[
"Oversedation, abuse potential"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"57ce9f",
"class":"cell txt l",
"children":[
"Caution in patients with kidney disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4f0812",
"class":"cell txt l",
"children":[
"Phenobarbital"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5da377",
"class":"cell txt l",
"children":[
"Treatment of status epilepticus and delirium tremens"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e7159b",
"class":"cell txt l",
"children":[
"Respiratory depression requiring airway protection"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cacc1b",
"class":"cell txt l",
"children":[
"Used in combination therapy for severe cases"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c5bed4",
"class":"cell txt l",
"children":[
"Propofol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5da377",
"class":"cell txt l",
"children":[
"Treatment of status epilepticus and delirium tremens"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e7159b",
"class":"cell txt l",
"children":[
"Respiratory depression requiring airway protection"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c40d1c",
"class":"cell txt l",
"children":[
"Caution in patients with severe cardiac disease"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"GABA = γ-aminobutyric acid; NMDA = ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"N"
]
},
"-methyl-",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"D"
]
},
"-aspartate."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Benzodiazepines are FDA pregnancy category X (contraindicated in pregnancy) or D (positive evidence of risk)."
]
]
},
"mk19_a_gm_t55":{
"id":"mk19_a_gm_t55",
"number":55,
"bookId":"gm",
"title":{
"__html":"Pharmacotherapy for Opioid Use Disorder"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"00af95",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 55. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gm_t55"
}
]
},
"Pharmacotherapy for Opioid Use Disorder"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"353bd6",
"class":"col hd l",
"children":[
"Medication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8ae2a5",
"class":"col hd l",
"children":[
"Uses"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b831dc",
"class":"col hd l",
"children":[
"Side Effects and Risks"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6b0217",
"class":"col hd l",
"children":[
"Precautions"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4c6f8",
"class":"col hd l",
"children":[
"Notes"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4cf38f",
"class":"cell txt l",
"children":[
"Methadone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6a0d11",
"class":"cell txt l",
"children":[
"Medication-assisted treatment for OUD"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6d5a81",
"class":"cell txt l",
"children":[
"Sedation, prolongation of the QT interval; similar to other opioids in terms of long-term use"
]
},
" ",
{
"type":"p",
"hlId":"9dc996",
"class":"cell txt l",
"children":[
"Risk for respiratory depression and overdose"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8241e5",
"class":"cell txt l",
"children":[
"Prolonged, variable half-life with incomplete cross-tolerance with other opioids; requires low initiation dose and slow titration"
]
},
" ",
{
"type":"p",
"hlId":"6e2e00",
"class":"cell txt l",
"children":[
"Potential for drug interactions with inducers or inhibitors of the P450 system"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b7afe4",
"class":"cell txt l",
"children":[
"U.S. schedule II"
]
},
" ",
{
"type":"p",
"hlId":"a342c3",
"class":"cell txt l",
"children":[
"For outpatient addiction treatment, only available through state-licensed programs"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1d341d",
"class":"cell txt l",
"children":[
"Buprenorphine-naloxone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6a0d11",
"class":"cell txt l",
"children":[
"Medication-assisted treatment for OUD"
]
},
" ",
{
"type":"p",
"hlId":"db67c8",
"class":"cell txt l",
"children":[
"Pain management for patients with concurrent OUD and pain syndromes requiring opioids (e.g., cancer-related pain)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"37a09e",
"class":"cell txt l",
"children":[
"Nausea, constipation, headache, insomnia"
]
},
" ",
{
"type":"p",
"hlId":"292916",
"class":"cell txt l",
"children":[
"Decreased risk for overdose; naloxone component activates if patient injects medication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0a4436",
"class":"cell txt l",
"children":[
"Risk for precipitated opioid withdrawal if initiated too soon in opioid-tolerant patient after last use of full opioid agonist"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"deeb9e",
"class":"cell txt l",
"children":[
"U.S. schedule III"
]
},
" ",
{
"type":"p",
"hlId":"0d5dc4",
"class":"cell txt l",
"children":[
"Requires specialized training (8-hour course) to obtain federal waiver to prescribe"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6b6106",
"class":"cell txt l",
"children":[
"Buprenorphine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"145a93",
"class":"cell txt l",
"children":[
"Inpatient withdrawal management"
]
},
" ",
{
"type":"p",
"hlId":"f51935",
"class":"cell txt l",
"children":[
"Maintenance, particularly for pregnant women"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"37a09e",
"class":"cell txt l",
"children":[
"Nausea, constipation, headache, insomnia"
]
},
" ",
{
"type":"p",
"hlId":"846337",
"class":"cell txt l",
"children":[
"Rarely associated with overdose, usually in combination with other sedating agents"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"091ccf",
"class":"cell txt l",
"children":[
"Risk for precipitated opioid withdrawal if initiated too soon after last use of full opioid agonist"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"deeb9e",
"class":"cell txt l",
"children":[
"U.S. schedule III"
]
},
" ",
{
"type":"p",
"hlId":"72dbe7",
"class":"cell txt l",
"children":[
"Requires federal waiver"
]
},
" ",
{
"type":"p",
"hlId":"0ce22d",
"class":"cell txt l",
"children":[
"Once-monthly injection formulation available"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"514561",
"class":"cell txt l",
"children":[
"Naltrexone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7c78eb",
"class":"cell txt li",
"children":[
"IM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10d0de",
"class":"cell txt l",
"children":[
"Maintenance"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e2311f",
"class":"cell txt l",
"children":[
"Nausea, fatigue, dizziness, injection site reaction"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4f06bf",
"class":"cell txt l",
"children":[
"Risk for overdose if a dose is missed and the patient relapses"
]
},
" ",
{
"type":"p",
"hlId":"6ea7a7",
"class":"cell txt l",
"children":[
"Periodic monitoring of liver enzymes is recommended; impaired metabolism in liver disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b1665a",
"class":"cell txt l",
"children":[
"Some variability in length of time for full opioid blockade"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1dfec3",
"class":"cell txt li",
"children":[
"Oral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6b332c",
"class":"cell txt l",
"children":[
"Bridge before IM naltrexone; maintenance in highly supervised settings"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3c07da",
"class":"cell txt l",
"children":[
"Nausea, headache, dizziness, elevated aminotransferase levels"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6ea7a7",
"class":"cell txt l",
"children":[
"Periodic monitoring of liver enzymes is recommended; impaired metabolism in liver disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"IM = intramuscular; OUD = opioid use disorder."
],
[
"Adapted with permission from Pace CA, Samet JH. In the clinic. Substance use disorders. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/AITC201604050",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2016;164:ITC58-ITC59. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27043992",
"target":"_blank"
},
"children":[
"PMID: 27043992"
]
},
". © 2016, American College of Physicians."
]
]
},
"mk19_a_gm_t56":{
"id":"mk19_a_gm_t56",
"number":56,
"bookId":"gm",
"title":{
"__html":"Personality Disorders"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"1f7a62",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 56. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gm_t56"
}
]
},
"Personality Disorders"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f0aadd",
"class":"col hd l",
"children":[
"Cluster A: Odd or Eccentric Thinking and Behaviors"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8c5d63",
"class":"cell txt l",
"children":[
"Paranoid: pervasive distrust of others; unjustified suspicion of others; unjustified suspicions regarding their partners or spouses; overly hostile reactions to perceived insults"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"02355c",
"class":"cell txt l",
"children":[
"Schizoid: prefer to be alone and lack interest in relationships; seem indifferent, cold, and unresponsive to social cues; take pleasure in few activities"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ee52a1",
"class":"cell txt l",
"children":[
"Schizotypal: manifest odd thinking, beliefs (e.g., their thoughts are magical and can influence others, events have hidden meaning), dress, and other behaviors"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"142564",
"class":"col hd l",
"children":[
"Cluster B: Dramatic or Unpredictable Thinking and Behaviors, Emotional"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8d9891",
"class":"cell txt l",
"children":[
"Antisocial: engage in such behaviors as lying, stealing, and other aggressive and violent behaviors; disregard others' feelings, rights, and safety; lack remorse for these behaviors; often experience recurrent legal problems"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"783d53",
"class":"cell txt l",
"children":[
"Borderline: have chaotic relationships (idealized and devalued) and a fragile self-image; fear abandonment; experience labile and intense emotions (e.g., anger), sense of emptiness; engage in impulsive and risky behaviors (e.g., gambling, sex); may manifest self-injury and suicidality"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"57b3d4",
"class":"cell txt l",
"children":[
"Histrionic: excessive emotionality and attention-seeking behavior; dramatic; often seductive or sexually provocative; melodramatic"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2d7670",
"class":"cell txt l",
"children":[
"Narcissistic: grandiose and inflated self-perceptions; desire attention"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bad384",
"class":"col hd l",
"children":[
"Cluster C: Anxious and Fearful Thinking and Behaviors"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3f01c2",
"class":"cell txt l",
"children":[
"Avoidant: feel inadequate and are sensitive to criticism; extremely shy and socially inhibited and avoid activities that involve interactions with others, especially strangers"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2f1b3c",
"class":"cell txt l",
"children":[
"Dependent: excessively dependent on others (“clingy”) and fear being alone; lack self-confidence and tolerate poor treatment by others"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"09581c",
"class":"cell txt l",
"children":[
"Obsessive-compulsive: perfectionistic and preoccupied with orderliness and rules; controlling of situations and others; rigid regarding values; not the same as obsessive-compulsive disorder, which is an anxiety disorder"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"Reproduced with permission from Schneider RK, Levenson JL. Psychiatry Essentials for Primary Care. Philadelphia: American College of Physicians; 2008."
]
]
},
"mk19_a_gm_t57":{
"id":"mk19_a_gm_t57",
"number":57,
"bookId":"gm",
"title":{
"__html":"Adverse Effects of Common Antipsychotic Medications"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"3e6754",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 57. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gm_t57"
}
]
},
"Adverse Effects of Common Antipsychotic Medications"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"353bd6",
"class":"col hd l",
"children":[
"Medication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c2c027",
"class":"col hd l",
"children":[
"EPS"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b6020e",
"class":"col hd l",
"children":[
"Elevated Prolactin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8e9eeb",
"class":"col hd l",
"children":[
"Anticholinergic Symptoms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"41da10",
"class":"col hd l",
"children":[
"Sedation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"95c025",
"class":"col hd l",
"children":[
"Weight Gain"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9490da",
"class":"col hd l",
"children":[
"Hyperlipidemia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"7"
},
"children":[
" ",
{
"type":"p",
"hlId":"23d2d9",
"class":"col hd l",
"children":[
"First-Generation Antipsychotics"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"761d45",
"class":"cell txt l",
"children":[
"Fluphenazine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ccd048",
"class":"cell txt l",
"children":[
"+/−"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26b172",
"class":"cell txt l",
"children":[
"+"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26b172",
"class":"cell txt l",
"children":[
"+"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26b172",
"class":"cell txt l",
"children":[
"+"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"af9209",
"class":"cell txt l",
"children":[
"Haloperidol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ccd048",
"class":"cell txt l",
"children":[
"+/−"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26b172",
"class":"cell txt l",
"children":[
"+"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26b172",
"class":"cell txt l",
"children":[
"+"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8bac41",
"class":"cell txt l",
"children":[
"Thiothixene"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26b172",
"class":"cell txt l",
"children":[
"+"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26b172",
"class":"cell txt l",
"children":[
"+"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"549949",
"class":"cell txt l",
"children":[
"−"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b6d375",
"class":"cell txt l",
"children":[
"Chlorpromazine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26b172",
"class":"cell txt l",
"children":[
"+"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5d1b0b",
"class":"cell txt l",
"children":[
"Thioridazine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26b172",
"class":"cell txt l",
"children":[
"+"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"549949",
"class":"cell txt l",
"children":[
"−"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"7"
},
"children":[
" ",
{
"type":"p",
"hlId":"a8d3e2",
"class":"col hd l",
"children":[
"Second-Generation Antipsychotics",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"66382e",
"class":"cell txt l",
"children":[
"Clozapine",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ccd048",
"class":"cell txt l",
"children":[
"+/−"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ccd048",
"class":"cell txt l",
"children":[
"+/−"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"116f37",
"class":"cell txt l",
"children":[
"+++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"116f37",
"class":"cell txt l",
"children":[
"+++"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1b254d",
"class":"cell txt l",
"children":[
"Risperidone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26b172",
"class":"cell txt l",
"children":[
"+"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26b172",
"class":"cell txt l",
"children":[
"+"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"394044",
"class":"cell txt l",
"children":[
"Olanzapine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26b172",
"class":"cell txt l",
"children":[
"+"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26b172",
"class":"cell txt l",
"children":[
"+"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26b172",
"class":"cell txt l",
"children":[
"+"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"116f37",
"class":"cell txt l",
"children":[
"+++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"116f37",
"class":"cell txt l",
"children":[
"+++"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"288839",
"class":"cell txt l",
"children":[
"Quetiapine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ccd048",
"class":"cell txt l",
"children":[
"+/−"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ccd048",
"class":"cell txt l",
"children":[
"+/−"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ccd048",
"class":"cell txt l",
"children":[
"+/−"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25fb0b",
"class":"cell txt l",
"children":[
"++"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"283df3",
"class":"cell txt l",
"children":[
"Aripiprazole"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26b172",
"class":"cell txt l",
"children":[
"+"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"549949",
"class":"cell txt l",
"children":[
"−"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"549949",
"class":"cell txt l",
"children":[
"−"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26b172",
"class":"cell txt l",
"children":[
"+"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26b172",
"class":"cell txt l",
"children":[
"+"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"549949",
"class":"cell txt l",
"children":[
"−"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"EPS = extrapyramidal symptoms."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Weight, blood pressure, fasting plasma glucose, and lipid levels should be monitored periodically."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Clozapine can also cause agranulocytosis and requires routine monitoring of blood counts."
]
]
}
}
}